Short hairpin RNA compositions, methods of making and applications thereof

ABSTRACT

Provided herein are novel synthetic short hairpin RNA (shRNA) molecules and compositions and kits comprising such molecules, as well as methods of making and using these molecules, compositions, and kits.

PRIORITY CLAIM

This application claims priority of U.S. Provisional Application No.62/096,838 filed Dec. 24, 2014, the subject matter of which is herebyincorporated by reference as if fully set forth herein.

BACKGROUND

Gene-silencing by siRNAs is a powerful technology for manipulating geneexpression and a potential therapeutic strategy for treating humandiseases. Canonical siRNAs are ˜21-nucleotide (nt) small RNAs that mimicproducts of Dicer processed double strand RNAs and can be incorporatedinto the RNA-induced-silencing-complex (RISC) to trigger the degradationof mRNA targets that contain highly complementary sequences (Elbashir2001). Canonical siRNAs are designed to resemble the biogenesisintermediates of microRNAs (miRNA), a family of endogenous small RNAsthat can repress the translation of target mRNAs that contain fully orpartially complementary sequences. Therefore, siRNA and miRNA share thesame functional machineries in the cell (Doench 2003; Zeng 2003).

The majority of miRNAs use Dicer to process the precursor-miRNAs(pre-miRNAs) to create 21 to 23-nt duplex RNAs that consist of onestrand from the 5′ arm (5p) and one strand from the 3′ arm (3p). The 3′end of each strand has an overhang of two nt. This duplex RNA is alsoreferred to as miRNA/miRNA*(the dominant strand/the less abundantstrand). Accordingly, siRNAs are designed as duplexes of antisensestrand/sense strand (guide strand/passenger strand) RNAs that are 21-ntlong, and have a 19 base pair dsRNA stem and an overhang of two nt atthe 3′ end of each strand (siRNA, FIG. 1A). In contrast, similarduplexes that have overhangs of two nt at the 5′ end (hereafter referredto as reverse siRNA or rsiRNA, FIG. 1B) are thought to be mostlyinactive (Elbashir 2001). DNA vector systems can also be used to expresssiRNAs as short hairpin RNAs (shRNAs, exp-shRNA), which can be used toexpress corresponding siRNAs in stable cell lines (McManus 2002;Brummelkamp 2002).

Several recent publications have revealed critical roles for loops,length of stems, and base pairing in the stem in exp-shRNA processingand silencing potency (Gu 2012; Herrera-Carrillo 2014; McIntyre 2011).In vitro T7 transcribed or chemically synthesized shRNAs (syn-shRNAs)were also shown to be potent RNAi triggers (Siolas 2005). The functionalstructure of syn-shRNAs was further characterized and the short stemversion was named as short shRNAs (sshRNA), which are Dicer-independent(Ge 2012; Dallas 2012). Despite its extensive application as aneffective gene manipulation reagent in research, the bright future ofRNAi therapeutics is shadowed by growing evidence that many siRNAs havetoxic side effects due to off-target activities of both the sense andanti-sense strands. These off-target effects will also produce biasedresearch data (Jackson 2003). Therefore, siRNA molecules that have apotent on-target effect and lack off-target activities are highlydesirable for both clinical and research applications. Despite extensivebodies of work accomplished in the past decade for this purpose, itremains a challenge to find an optimized siRNA for a specific target.Thus, there is a need for detailed parameters that can be used toeffectively create optimal shRNAs that can be further processed intopotent siRNAs.

SUMMARY

One aspect provided herein relates to a synthetic short hairpin RNA(shRNA) molecule designed to silence the expression of a target genecomprising a 5′ arm and a 3′ arm comprising a stem region comprising 16,17 or 18 base pairs, the base pairs comprising nucleotides from the 5′arm paired with nucleotides from the 3′ arm, and one or more unpairednucleotides at the 5′ terminal end of the 5′ arm and one or moreunpaired nucleotides at the 3′ terminal end of the 3′ arm; and a loopregion comprising 4 nucleotides that connects the 5′ arm to the 3′ arm,wherein the shRNA molecule is processed by Argonaute 2 (Ago2) in aDicer-independent manner. In certain embodiments, the stem region of theshRNA molecule may be 17 base pairs and the shRNA molecule consists of40 nucleotides, wherein the first nucleotide positioned at the 5′terminal end of the 5′ arm is designated as p1 and the last nucleotidepositioned at the 3′ terminal end of the 3′ arm is designated as p40. Incertain embodiments, an Ago2 nick site may be located near the middle ofthe 3′ arm. In certain embodiments, the Ago nick site may be locatedbetween nucleotides p30 and p31. In certain embodiments, an antisenseregion may comprise the 5′ arm and the loop region (i.e., nucleotidesp1-p22) and a sense region may comprise the 3′ arm (i.e., nucleotidesp23-p40). In certain embodiments, when the shRNA is 40 nts, theantisense region may comprise a seed region comprising nucleotidesp2-p8, a central region comprising nucleotides p9-p12, a 3′supplementary region comprising nucleotides p13-p17 and a tail regioncomprising nucleotides p18-p22. In certain embodiments, the seed regionis fully complementary to a portion of a target RNA sequence of thetarget gene and the 3′ supplementary region is generally complementaryto a portion of the target RNA sequence of the target gene. In certainembodiments, the target RNA sequence comprises a messenger RNA sequenceof the target gene. In certain embodiments, the nucleotide sequence ofthe tail region may be fully complementary to a portion of the targetnucleotide sequence. In certain embodiments, the base pairs of the stemregion may comprise nucleotides p2-p18 from the 5′ arm base paired withnucleotides p39-p23 from the 3′ arm, respectively (i.e., p2:p39, p3:p38,p4:p37, p5:p36, p6:p35, p7:p34, p8:p33, p9:p32, p10:p31, p11:p30,p12:p29, p13:p28, p14:p27, p15:p26, p16:p25, p17:p24, and p18:p23). Incertain embodiments, the base pairs formed between nucleotides p2-p17and nucleotides p39-p24, respectively, may form fully complementary basepairs. In certain embodiments, the base pair formed between nucleotidesp18 and p23 may form through a guanine (G):uracil (U) (i.e., G:U) or U:Gwobble base pair. In certain embodiments, the unpaired nucleotide at the3′ terminal end of the 3′ arm may be a cytosine (C). In certainembodiments, the one or more unpaired nucleotide at the 5′ terminal endof the 5′ arm is not phosphorylated. In certain embodiments, the one ormore unpaired nucleotide at the 5′ terminal end of the 5′ arm may be anadenine (A) or a U. In certain embodiments, when the shRNA molecule is asynthetic shRNA molecule, the one or more unpaired nucleotide at the 5′terminal end of the 5′ arm may be two A's. In certain embodiments, whenthe shRNA molecule is a synthetic shRNA molecule, the one or moreunpaired base at the 3′ terminal end of the 3′ arm may be twodeoxythymidine nucleotides (i.e., dTdT) and a C, wherein the C may bepositioned 5′ relative to the dTdTs. In certain embodiments, when theshRNA molecule is a synthetic shRNA molecule, the one or more unpairedbase at the 3′ terminal end of the 3′ arm may be one dideoxycytidinenucleotide (i.e, ddC). In certain embodiments, the shRNA molecule may beexpressed by a vector (i.e., vector expressed shRNA). In certainembodiments, when the shRNA molecule is a vector expressed shRNA, theone or more unpaired nucleotides at the 5′ terminal end of the 5′ armmay be one A.

Another aspect provided herein relates to a vector comprising anucleotide sequence encoding any one or more of the vector expressedshRNA molecules as described herein. In certain embodiments, the vectormay be a conditional expression vector comprising a U6 promoter to driveexpression of the one or more shRNA molecules. In certain embodiments,the vector may be an inducible expression promoter comprising adoxycycline [dox]-inducible U6 (U6TO) promoter to drive expression ofthe one or more shRNA molecules.

Another aspect provided herein relates to a cell comprising any one ormore of the vectors comprising a nucleotide sequence encoding any one ormore of the vector expressed shRNA molecules as described herein. Incertain embodiments, the cell may be a mammalian cell. In certainembodiments, the cell may be infected with a virus comprising the vectoras described herein. In certain embodiments, the virus may be alentivirus.

Another aspect provided herein relates to a method of designing asynthetic shRNA molecule comprising designing any of the synthetic shRNAmolecules as described herein. In certain embodiments, antisense strandselection software may be used to design the shRNA molecule.

Another aspect provided herein relates to a method of silencingexpression of a target nucleotide sequence comprising obtaining a samplecomprising the target nucleotide sequence, and providing any of thesynthetic shRNA molecules described herein and/or vectors comprising anucleotide sequence encoding any one or more of the vector expressedshRNA molecules as described herein to the sample. In certainembodiments, production of unwanted sense strand is reduced.

Another aspect provided herein relates to a method of treating a subjecthaving a disease or condition comprising administering a therapeuticallyeffective amount of one or more of any of the synthetic shRNA moleculesdescribed herein to the subject.

Another aspect provided herein relates to a method of treating a subjecthaving a disease or condition comprising administering a vectorcomprising a nucleotide sequence encoding one or more of the vectorexpressed shRNA molecules as described herein to the subject. In certainembodiments, a therapeutically effective amount of the one or morevector expressed shRNA molecules may be expressed by the vector.

Also provided herein are compositions, formulations and kits comprisingthe synthetic shRNA molecules, vector expressed shRNA molecules, orvectors comprising nucleotides sequences encoding one or more vectorexpressed shRNA molecules as described herein.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A, 1B and 1C show Ago-2 sliced siRNA (i.e., sli-siRNA) molecules.FIG. 1A shows a schematic of the secondary structures of siRNA with a 3′end overhang of two nts. Nucleotides 1-21 of the 5′ arm of the siRNAmolecule make up the antisense strand and nucleotides 1-21 of the 3′ armof the siRNA molecule make up the sense strand. FIG. 1B shows reversesiRNA (i.e., rsiRNA) with a 5′ end overhang of two nucleotides (nts).Nucleotides 1-21 of the 5′ arm of the rsiRNA molecule make up theantisense strand and nucleotides 1-21 of the 3′ arm of the rsiRNAmolecule make up the sense strand. FIG. 1C shows the canonical structureof the synthetic version of sli-siRNA (i.e., agsiRNA) and the expressedversion of sli-siRNA (i.e., agshRNA). The thick vertical lines representbase pairing. Nucleotides 1-18 of the 5′ arm and nucleotides 19-22 ofthe loop make up the antisense strand. Nucleotides 23-40 of the 3′ armmake up the sense strand.

FIGS. 2A, 2B and 2C show the structure of human pre-miR-451. FIG. 2Ashows the secondary structure of pre-mi-451. The sequence of the 5′ arm(5p) including the stem loop is the mature miR-451. The short fragmentgenerated by Ago2 from 3p is shown in dark grey on the bottom left(i.e., sequence 3′-CUCUUGGUAAUG-5′), and the light grey bases on thebottom right from the 3p (i.e., sequence 3′-GUAAUGAU-5′) were trimmedduring miR-451 maturation. FIGS. 2B and 2C show tertiary and surfacerepresentations, respectively, of the predicted structures ofhsa-pre-miR-451 without the last 3′ UC bases.

FIG. 3 shows an alignment of pre-miR-451 from 18 species found inmiRBase 19.

FIGS. 4A, 4B and 4C show the characterization of pre-miR-451. FIG. 4Ashows an alignment of 18 species of pre-miR-451 from miRBase 19. FIGS.4B and 4C show predicted tertiary structures of hmiR-451 aligned withmmiR-451, and hmiR-451 aligned with dmiR-451, respectively.

FIG. 5 shows a table of the properties of pre-miR-451 versus siRNAmolecules. Abbreviations are as follows: “wc”=Watson-Crick base pairs;“wb”=wobble base pairs; “mm”=mismatch base pairs. The asterisk (“*”)indicates bases that are only present in pma-pre-miR-451.

FIG. 6 shows schematic representations of agshRNA expression constructs.Two oligonucleotides were ordered for each agshRNA. The forward strandoligonucleotide had the 5′ overhang GATC, followed by the agsiRNAsequence, then five Ts at the 3′ end. The reverse strand oligonucleotidehad the 5′ overhang TCGA, followed by five ‘A’s, then the agsiRNAcomplementary sequence. The GATC and TCGA overhangs are complementary tothe ends of U6-agshRNA and U6TO-agshRNA after digestion by Bgl II andXho I, respectively. The Not I to Xba I fragment from U6-agshRNA wassubcloned into the Not I and Xba I sites of the lentiviral vectorSSFVLV-Puro to produce SSFVLV-U6-agshRNA-Puro, which can generate stablecell lines that constitutively express agshRNA. The Not I to Xba Ifragment from a Doxycycline [Dox]-inducible U6m (U6TO)-agshRNA wassubcloned into the Not I and Xba I sites of the lentiviral vectorCMVLV-TIP (TetR-IRES-Puro) to produce CMVLV-U6TO-agshRNA-TIP, which cangenerate stable cell lines that can be induced to express agshRNA.

FIG. 7 shows the secondary structures predicted by mFold for theagshRNAs designed to target R2.

FIGS. 8A, 8B, 8C and 8D show data for agshRNAs that target R2. FIG. 8Ashows Western blots of R2 targeted by agshRNAs. Vector indicates theU6-agshRNA. Actin was used as the loading control. FIG. 8B shows Westernblots comparing the activity of the canonical form of agshRNA with theG:U form and mismatched forms (mmp7). Vector indicates the U6m-agshRNA.Actin was used as the loading control. FIG. 8C shows a reporter assay ofagshRNA designed to target R2. The R2 coding sequence (NCBI referencesequence: NM_001165931.1) and reverse sequence were cloned into the3′UTR of Rluc gene in psiCheck2.2 to make reporters for R2-CDS andR2-CDS-reverse. These constructs measured the 5p and 3p activity ofagshRNAs designed to target R2. Rluc/Fluc ratios are plotted. Error barsrepresent the standard deviation. FIG. 8D shows reporter assays tomeasure the 5p and 3p activity of the wt, mmp7, and GU forms. Rluc/Flucratios are plotted. Error bars represent the standard deviation.

FIG. 9 shows a table listing the length distributions of the 5p and 3parms from various agshRNAs after processing by Ago2. The full sequencefor each agshRNA construct is provided and the sequence of the loopregion is bolded and underlined.

FIGS. 10A, 10B and 10C show the single molecular folding form and crossmolecular hybridization form of agsiRNA. FIG. 10A shows the secondarystructure predicted by the RNA structure of the single molecular foldingform (SMFF) of hmiR-451. FIG. 10B shows the secondary structurespredicted by RNA structure of the cross molecular hybridization form(CMHF) of hmiR-451 and its potential products when processed by Dicer.Anti-sense strands are designated as A21 and A19 and sense strands aredesignated 21C and 19C. FIG. 10C shows a schematic of the processing ofagsiRNA CMHF (A-S17-L4-C) into A21, A19, 21C, and 19C by Dicer.

FIG. 11 shows the structures predicted by mFold for agsiRNA-887,agsiRNA-887-mut, and agshRNA-887.

FIG. 12 shows sli-siRNA-887 and variants. Variants of agsiRNA-887 usedin Example 1 were made by replacing nt(s) in the backbone or addingextra nt(s) to the 5′ end or 3′ end of the molecule. Based on the wtagsiRNA-887 backbone, modifications were made as following: replacing ofthe anchor ‘A’ (p1) with uracil (“U”) or a cytosine (“C”) to makeU/C-S17-L4 forms; prefixing the anchor ‘A’ (p1) with an adenine (“A” or“a”), ‘aa’, ‘aaaa’, or ‘aaaaa’ to make 5′ overhang variantsa/aa/aaa/aaaa-A-S17-L4; mismatch base pairing at p6:35, p7:34, p8:33,p13:28, p14:27, and p15:26 to make the mmp6, mmp7, mmp8, mmp13, mmp14,and mmp15 forms, respectively; replacing the ‘C’ at p33 with an ‘U’ tomake the GUp8 form; replacing the p31, p30 and p29 bases with the p10,p11 and p12 bases to make the mutant (mut) form; Replacing the ‘C’ atp40 with a dideoxycytidine (“ddC”) to make the ‘ddC’ form; adding one‘U’, two CU's, five ‘U’s, or two deoxythymidines (“dTs”) to the ‘C’ atp40, respectively, to make the U, 2U, 5U, and dTdT forms; replacing ‘G’at p39 with ‘C’ to make mmp2 form; replacing ‘G’ at p39 with ‘C’ and ‘U’at p38 with ‘A’ to make mmp2-3 form; replacing ‘U’ at p23 with ‘C’ tomake p18GC; replacing the ‘U’ at p23 with a guanine (“G”) to make mmp18;replacing the ‘U’ at p23 with a ‘G’ and the ‘U’ at p24 with an ‘A’ tomake mmp17-18; replacing the ‘U’ at p23 with a ‘C’, an ‘U’ at p24 withan ‘A’, and the ‘A’ at p25 with an ‘U’ to make mmp16-17-18

FIGS. 13A, 13B, 13C and 13D show the predicted secondary structures ofsli-siRNA-887 variants used in this study. FIG. 13A shows the secondarystructure of agsiRNA-887 (the L40, S17, or wild-type forms) and some ofthe variants used in this study. Mismatches were introduced at p18:23 tomake the mmp18 form, at p18:23 and p17:24 to make the mmp17-18 form, atp18:23, p17:24, and p16:25 to make the mmp16-17-18 form, at p6:35 tomake the mmp6 form, at p7:p34 to make the mmp7 form, at p2:39 to makethe mmp2 form, at p2:p39 and p3:p38 to make the mmp2-3 form. FIG. 13Bshows the secondary structure of agshRNA-887-GUp8 (with the p33 Creplaced by a U) and the bulge-p7 (which has the G at p34 removed). Thefirst 19 nt of agsiRNA-887 were directly connected to its complementarysequence to make the non-loop version (NL). UU was used to connect thefirst 19 nt of agsiRNA-887 to its complementary sequence, to make theshort shRNA version (ssh). FIG. 13C shows the secondary structure of thestem variants of sli-siRNA-887. Longer stem variants (agshRNA-887 only)were created by adding nt to the end of the L22 form, using antisensesequences to RRM2 mRNA, and using the last 4 nt to make the loop. S17,wt; S18, perfect base pair at p19 was added to the stem. S19: perfectbase pair at p19 and p20 were added to the stem. S20: perfect base pairat p19, p20, and p21 were added to the stem. The short stem variantsS16, S15, S14, S13, S12, and S11 (for both agsiRNA and agshRNA), werecreated by removing nt from the end of the L22 form, one nt at a time,and using the last 4 nt of the trimmed sequence to make the loop (Theend Cs of the S11, S12, and S13 forms were removed unintentionally).FIG. 13D shows the secondary structures of length variants ofagsiRNA-887. Variants were created by trimming nt from the 3′ end of L40(wt) to make the L39 to L25 forms.

FIGS. 14A and 14B show results from northern blot analyses ofagshRNA-887 and agsiRNA-887 in Dicer^(−/−), Ago2^(−/−), and wild-typeMEFs. FIG. 14A shows the results for agshRNA-887. FIG. 14B shows theresults for agsiRNA-887. The abbreviations are as follows: w=wild-type;m=mutant; c=control sli-siRNA with a scrambled sequence. Both U2 and U6snoRNAs were used as RNA loading controls.

FIG. 15 shows a bar graph of results from reporter assays ofsli-siRNA-887, rsiRNA-887, and siRNA-887 in Dicer^(−/−), Ago2^(−/−), andwild-type MEFs. Results from MEFs are represented by the bar on theleft, results from Ago2^(−/−) (i.e., Ago2KO) are represented by themiddle bar, and results from Dicer^(−/−) (i.e., DicerKO) are representedby the bar on the right. Abbreviations are as follows: mmp7: mismatchfor base #7 with #34; wt, GU: mutated base #33 from C to U.

FIG. 16 shows results from antisense strand (5p) reporter assays inHCT-116 cells. Abbreviations are as follows: rsi=rsiRNA-887;si=siRNA-887; L30-3L12 is agsiRNA-887 that was reconstituted byannealing 3L12 with L30. Rluc/Fluc ratios are plotted. Error barsrepresent the standard deviation.

FIG. 17 shows results from sense strand (3p) reporter assays ofagsiRNA-887 (wt), rsiRNA-887 (rsi), and siRNA-887 (si) in HCT-116 cells.Rluc/Fluc ratios are plotted. Error bars represent the standarddeviation.

FIGS. 18A, 18B, 18C, 18D, 18E, 18F and 18G show results from reporterassays of agsiRNA-887 variants. FIG. 18A shows dose-dependent reporterassays of agsiRNA-887 (agsi887) and agsiRNA-887 that had a monophosphateat the 5′ end (P-agsi887). Rluc/Fluc ratios are shown. Error barsrepresent the standard deviation. FIG. 18B shows reporter assays ofagsiRNAs in which anchor bases were replaced. The anchor nt A inagsiRNA-887 was replaced with a U or a C. Rluc/Fluc ratios are shown.Error bars represent the standard deviation. FIG. 18C shows reporterassays for 5′ end prefixing variants of agsiRNA-887 in HCT-116 cells.Rluc/Fluc ratios are shown. Error bars represent the standard deviation.FIG. 18D shows a comparison of the agsiRNA-887 3′ overhang: wt versus UUand dTdT forms in HCT-116 cells. Rluc/Fluc ratios are plotted. Errorbars represent the standard deviation. FIG. 18E shows a comparison ofthe agsiRNA-887 3′ overhang: wt versus U and ddC forms in HCT-116 cells.Rluc/Fluc ratios are plotted. Error bars represent the standarddeviation. FIG. 18F shows a comparison of agsiRNA-887-wt versus the-mmp2, -mmp2-3, -mmp,6 and -mmp7 forms in HCT-116 cells. Rluc/Flucratios are plotted. Error bars represent the standard deviation. FIG.18G shows reporter assays of loop variants of agsiRNA-887 in HCT-116cells. ‘p18GU’ is wt. Rluc/Fluc ratios are shown. Error bars representthe standard deviation.

FIGS. 19A, 19B, 19C, 19D, 19E, 19F, 19G and 19H show thecharacterization of sli-siRNA-887. FIG. 19A shows a Northern blot todetect the processed products from agsiRNA-887 that have extra bases onthe 5′ or 3′ end in transfected HEK-293 cells. Ctrl, scrambled agsiRNA.U2 and U6 snoRNAs were used as RNA loading controls. FIG. 19B shows aNorthern blot to detect the processed products of base and loop modifiedagsiRNA-887 in transfected HEK-293 cells. U2 snoRNA was used as the RNAloading control. FIG. 19C shows a Northern blot to detect the processedproducts of agshRNA-887 variants expressed by the U6m promoter intransfected HEK-293 cells. U6 snoRNA was used as the RNA loadingcontrol. FIG. 19D shows a Northern blot to detect the processed productsof stem variants of agshRNA-887 in transfected HEK-293 cells. Ctrl,scrambled agshRNA; S17, the wt agshRNA-887; mut, agshRNA-887non-cleavable mutant; U1, S17 driven by a modified U1 promoter; H1, S17driven by a modified H1 promoter. All other agshRNAs were transcribedfrom U6m. U2 and U6 snoRNAs were used as RNA loading controls. FIG. 19Eshows a Northern blot to detect the processed products of stem variantsof agsiRNA-887 in transfected HEK-293 cells. Ctrl, agsiRNA with ascrambled RNA sequence; S17, the wt agsiRNA-887; rsi, rsiRNA-887; si,siRNA-887. U2 and U6 snoRNAs were used as RNA loading controls. FIG. 19Fshows results from reporter assays of HCT-116 cells transfected with theagsiRNA-887 stem variants. Rluc/Fluc ratios are shown. Error barsrepresent the standard deviation. FIG. 19G shows a Northern blot todetect the processed products of agsiRNA-887 that have length variationsin transfected HEK-293 cells. Ctrl, agsiRNA with a scrambled sequence;mut, agsiRNA-887-mut. The weak band in L38 was unintentionally caused byusing only 1/10 of the molar concentration used for the others fortransfection. U2 and U6 snoRNAs were used as RNA loading controls. FIG.19H shows reporter assays of HCT-116 cells transfected with agsiRNA-887that have length variations. Rluc/Fluc ratios are shown. Error barsrepresent the standard deviation.

FIGS. 20A, 20B and 20C show cleavage of fully complementary targets andthe repression of partially complementary targets by agsiRNA-451 orsRNA-451. FIG. 20A shows a time course analyses of target knockdown whenthe target sequence is a perfect complement. Three miRNA-451 variants(hmiR-451, mmiR-451, dmiR-451) and sRNA-451 (si-451) were compared.Reporters and siRNAs (80 pM) were co-transfected into HCT-116 cells.Rluc/Fluc ratios are shown. Error bars represent standard deviation.Data for 12 hour, 24 hour, 36 hour, and 48 hour time points arerepresented by the bars in order from left to right, respectively. FIG.20B shows results from reporter assays showing repression of partiallycomplementary targets by hmiR-451 and sRNA-451 (80 pM). Rluc/Fluc ratiosare bar plotted and grouped by RNAi molecules. Error bars representstandard deviation. FIG. 20C shows the sequences of four types ofrepression reporters. Each vector carried four copies of the same targetsequence in tandem: 1) miR-451 seed sequence (SeedX4); 2) Seed plussequence that base paired with the 3′supp region (Seed-3SuppX4); 3) Seedthat had the middle base mutated plus 3Supp (mSeed-3SuppX4); and 4) Seedplus 3Supp that had the middle base mutated (Seed-m3SuppX4). Data formSeed-3Suppx4, SeedX4, Seed-3SuppX4, and Seed-m3SuppX4 targets arerepresented by the bars in order from left to right, respectively.

FIGS. 21A, 21B, 21C and 21D show results from reporter assays oftail-base replacements in HCT-116 cells. FIG. 21A shows results from areporter assay in which the bases from p18 to p23 (tail-bases) ofagsiRNA-887 were replaced with the tail bases of hmiR-451 (GAGUUU:LP451). Rluc/Fluc ratios are plotted. Error bars represent the standarddeviation. FIG. 21B shows results from a reporter assay in which thetail-bases of hmiR-451 were replaced with the tail bases of agsiRNA-887(GGAUGU: LP887). Rluc/Fluc ratios are plotted. Error bars represent thestandard deviation. FIG. 21C shows results from a reporter assay inwhich the tail-bases of agsiRNA-1148 were replaced with LP451 or LP887.Rluc/Fluc ratios are plotted. Error bars represent the standarddeviation. FIG. 21D shows results from a reporter assay in which thetail-bases of agsiRNA-1354 were replaced with LP451 or LP887. Rluc/Flucratios are plotted. Error bars represent the standard deviation.

FIG. 22 shows a northern blot analysis to detect products processed fromsli-siRNA-887 in HEK-293 cells. Transfected cells were split at days 1,2, 4, and 6 post-transfection, and total RNA was isolated on days 1, 2,4, 6, and 8 post-transfection. Blots were probed with 887-5p. U2 and U6snoRNAs were used as the RNA loading controls.

FIG. 23 shows data illustrating the immune response to sli-siRNA-887 inHEK-293 cells. Expression of the innate immune response genes IRF9,IFITM1, and CDKL was analyzed by qPCR in HEK-293 cells transfected withthe sli-siRNA-887, -mut, -mmp7, and -GU forms.Polyinosinic:polycytidylic acid (poly I:C), which stimulates innateimmune responses, was used as the positive control. Data were normalizedto GAPDH and calculated by ΔΔCt method. Data for the innate immuneresponse genes IRF9, IFITM1, and CDKL are represented by the bars inorder from left to right, respectively.

FIGS. 24A, 24B, 24C and 24D show sli-siRNAs targeting R2 partners.Sli-siRNAs were designed to target RR subunit M1 (RRM1 or R1,NM_001033.3) and RR subunit M2B (RRM2B or R2B, also called p53R2,NM_015713), which are the other enzymes in the RR complex. FIG. 24Ashows predicted secondary structures of the agsiRNAs that target R1.FIG. 24B shows a Western blot analysis of RRM1 from HEK-293 cellstransfected with sli-siRNAs targeting R1. The control (Ctrl) for agsiRNAwas agsiRNA containing a scrambled sequence. The Ctrl for agshRNA wasthe U6-agshRNA containing a scrambled sequence. Actin was used as theloading control. Two of the three sli-siRNAs designed to target R1(R1-445 and -2290) reduced R1 protein levels. FIG. 24C shows predictedsecondary structures of agsiRNAs that target R2B. FIG. 24D shows Westernblot analysis of R2B from HEK-293 cells transfected with sli-siRNAstargeting R2B. The Ctrl for agsiRNA was the agsiRNA containing ascrambled sequence. The Ctrl for agshRNA is the U6-agshRNA containing ascrambled sequence. Actin was used as the loading control. One of thethree sli-siRNAs designed to target R2B (R2B-948) reduced R2B proteinlevels.

FIGS. 25A, 25B, 25C, 25D and 25E show the results from the applicationof sli-siRNA-1148 in mammalian cells. FIG. 25A shows a Northern blotanalysis of products processed from agshRNA-1148. Blots were preparedfrom total RNA extracted from HEK-293 cells transiently transfected withU6-agshRNA-1148, -mmp7, -GU, U1-agshRNA-1148, and H1-agshRNA-1148. U2and U6 snoRNA were used as loading controls. When under the control ofthe U1 and H1 promoters, agshRNA-1148 expression levels were so low thatthe processed product was barely detectable (U1) or undetectable (H1).FIG. 25B shows qPCR of miR-21 (very high expression), miR-31 (highexpression), and miR-143 (low expression) in HCT-116 cells lines thatconstitutively expressed agshRNA-1148. Data were normalized to U6 snoRNAand calculated by the ΔΔCt method. Data for the miR-21, miR-31 andmiR-143 constructs are represented by the bar graphs in order from leftto right, respectively. FIG. 25C shows real time cell growth as measuredby the RT-CES system. HCT-116 cells transduced by lentiviral vector(vector), agshRNA with a scrambled sequence (ctrl), mutated agshRNA-1148(mut, Ago2 cleavable, bases from p10-11-12 were exchanged with basesfrom p31-30-29; the processed product can repress RRM2 mRNA), wt, mmp7,and the GU forms were plated and measured every 30 min for two days.Cell indexes, which correspond to the number of cells in the chambers,were plotted against time. FIG. 25D shows the invasion of HCT-116 celllines constitutively expressing agshRNA-1148 and several variants ofagshRNA-1148, as described in (C). Cell invasion assays were performedonce for 24 h and twice for 48 h. Infiltrated cells were stained withDiff-Quik and counted. Three regions of each assay well were randomlychosen, and cells within these regions were counted. The 48 h data arean average of two independent experiments. FIG. 25E shows images from awound healing assay of stable HCT-116 cell lines constitutivelyexpressing agshRNA-1148 and variants described in (C). Cells plated in24-well plates were scratched and floating cells were washed away.Images shown were taken immediately after making the scratch (upperpanels) and after 48 h (lower panels).

FIGS. 26A, 26B, 26C and 26D show in vivo knock down of R2 in HCT-116cells by agshRNA-1148. FIG. 26A shows a Western blot analysis of R2 inHCT-116 cell lines constitutively expressing agshRNA-1148 and itsvariants. Actin was used as loading control. FIG. 26B shows qPCR resultsof R2 mRNAs in HCT-116 cell lines constitutively expressing agshRNA-1148and its variants. Data was normalized to GAPDH, and then to the vector.Error bars represent standard deviation. FIG. 26C shows Northern blotsof the processed products in HCT-116 cell lines constitutivelyexpressing agshRNA-1148 or variants. U2 and U6 snoRNAs were used as RNAloading controls. FIG. 26D shows Northern blots of processed products inHCT-116 cell lines that were induced by Dox to express agshRNA-1148 andcorresponding western blots of the R2 protein levels. U6 snoRNA was usedas the RNA loading control, and GAPDH was used as the cell extractloading control.

FIGS. 27A, 27B and 27C show comparisons of agshRNA-887, -1148 and -1354expressed by the U6, U1 and H1 promoters. FIG. 27A shows results whereinreporter constructs containing agshRNA-887 expressed by the U6, U1 or H1promoters were transfected into HCT-116 cells and assayed. Rluc/Flucratios are plotted. Error bars represent the standard deviation. FIG.27B shows results wherein reporter constructs containing agshRNA-1148expressed by the U6, U1 or H1 promoter were transfected into HCT-116cells and assayed. Rluc/Fluc ratios are plotted. Error bars representthe standard deviation. FIG. 27C shows results wherein reporterconstructs containing agshRNA-1354 expressed by the U6, U1 or H1promoter were transfected into HCT-116 cells and assayed. Rluc/Flucratios are plotted. Error bars represent the standard deviation.

FIG. 28 shows a table of the sequences of shRNAs, siRNAs, PCR primersand probes used for Northern blot analysis, and U6+multiple cloningsites (MCS) and U6TO+MCS. For the shRNAs and the siRNAs, nucleotidesthat form the antisense strands are underlined, nucleotides that formthe loops are italicized and nucleotides that form the sense strands arebolded. For the U6TO+MCS, the nucleotides of the tet binding element areunderlined and bolded. The corresponding SEQ ID NOs (i.e., SEQ ID NOs:1-144) are listed for all of the sequences.

FIGS. 29A and 29B show the U6 promoters that were used to expressagshRNA. FIG. 29A shows the sequence for U6+MCS (SEQ ID NO: 143). FIG.29B shows the sequence for U6TO+MCS (SEQ ID NO: 144). For the U6TO+MCSsequence, the nucleotides of the tet binding element are underlined andbolded. The promoter and MCS were cloned into pcDNA3.1-Neo. ThepcDNA3.1-Neo vector was modified as follows: 1) the CMV promoter wasremoved, 2) the Bgl II site was mutated to a BamH I site, and 3) eitherU6 or U6TO with MCSs was cloned into Bam HI and Xba sites.

FIGS. 30A, 30B and 30C show schematic illustrations of di-siRNA,sli-siRNA or siRNA targeting. FIG. 30A shows di-siRNA targeting.Nucleotides 1-21 of the 5′ arm make up the antisense strand andnucleotides 1-21 of the 3′ arm make up the sense strand. FIG. 30B showssli-siRNA targeting. Nucleotides 1-22 make up the antisense strand,nucleotides 23-30 are uridylated and trimmed bases and nucleotides 31-40make up the sense strand. FIG. 30C shows siRNA targeting. Nucleotides1-21 of the 5′ arm make up the antisense strand and the nucleotides ofthe 3′ arm make up the target RNA.

FIG. 31 is a table showing the sequences of sli-siRNAs and di-siRNAsused for the experiments performed in Example 2. Nucleotides that formanti-sense strands are underlined, nucleotides that form loops forsli-siRNAs are italicized, nucleotides that form sense strands arebolded.

FIG. 32 shows highly complementary reporters designed for sli-siRNA-887.Mismatched reporters designed. Each position has two reporters withdifferent single base mutations. U6G-U12G and U4C-U15C are reportersthat carry two mutations.

FIG. 33 shows highly complementary target knockdown by sli-siRNA-887 anddi-siRNA-887 (about 200 fmol). Normalized Rluc/Fluc ratios are plottedaccording to the mutation and corresponding position number of the basesin the sli-siRNA or di-siRNA. Error bars represent standard deviation.

FIG. 34 shows box plots and statistical analysis of data shown in FIG.33. Data are plotted and grouped by all targets (All), targets withmutations in the seed region (seed), and mutations in the 3supp region(3supp). Paired student's T-test was used to calculate the P values astwo-tailed 95% confidence intervals.

FIG. 35 shows knockdown of highly complementary targets by sli-siRNA-887and di-siRNA-887 mutants (400 fmol): G14C perfectly complementssli-siRNA-887-C14G and di-siRNA-887-C14G (p14 C was mutated to a G).G14A perfectly complements sli-siRNA-887-C14U and di-siRNA-887-C14U (p14C was mutated to a U). A9U and A9C are mutated reporters for all threeof the sli-siRNAs and di-siRNAs. Error bars represent standarddeviation.

FIG. 36 shows highly complementary reporters designed forsli-siRNA-ARX1. Mismatched reporters designed. Each position has tworeporters with different single base mutations.

FIG. 37 shows highly complementary target knockdown by sli-siRNA-ARX1 vsdi-siRNA-ARX1. About 12.5 fmol was used for each transfection toknockdown the fully complementary target at about 80%. NormalizedRluc/Fluc ratios are plotted according to the mutation and correspondingposition number of the bases in the sli-siRNA or di-siRNA. Error barsrepresent standard deviation. di-siRNA data is represented by the topline and sli-siRNA is represented by the bottom line in the graph.

FIG. 38 shows highly complementary reporters designed for sli-siRNA-451.Mismatched reporters designed. Each position has two reporters withdifferent single base mutations.

FIG. 39 shows knockdown of highly complementary reporters by mmiR-451(sli-451) and siRNA-451 (si-451). About 6.5 fmol was used for eachtransfection to knockdown the fully complementary target at about 80%.Data are 3-D area plotted according to the mutations and correspondingposition number of the bases in the siRNA. Normalized Rluc/Fluc ratioswere used.

FIG. 40 shows box plots and statistical analysis of data shown in FIG.39. Data are plotted and grouped by all targets (All), targets withmutations in the seed region (Seed), and targets with mutations in the3′supp region (3Supp). Paired student's t-test was used to calculate theP values as two-tailed 95% confidence intervals.

FIGS. 41A and 41B show iso-miRs of mmu-miR-451 and functional model ofsli-smRNA. FIG. 41A is a table showing the top ten iso-miRs ofmmu-miR-451. Raw reads for mmu-miR-451a (accession #MI000173) wereoriginally from miRBase 19. Reads at the 5′end are AAA- and AA-formswere combined for further classification (the combined reads are 244,817from total 272,429 isomiRs) according to bases at the 3′ end thatmatched the mmu-pre-miR-451 sequence. FIG. 41B is a pie graph showingthe top ten isomiRs of mmu-miR-451 in miRBase were plotted by length.

FIGS. 42A and 42B show schematic representations. FIG. 42A shows aschematic representation of proposed function model of sli-smRNA versusdi-smRNA. FIG. 42B shows a schematic representation of Ago2 molecule.

FIG. 43 shows a schematic representation of the proposed working modelsfor sli-RISC versus di-RISC.

DETAILED DESCRIPTION

The following description provides specific details for a thoroughunderstanding of, and enabling description for, embodiments of thedisclosure. However, one skilled in the art will understand that thedisclosure may be practiced without these details. In other instances,well-known structures and functions have not been shown or described indetail to avoid unnecessarily obscuring the description of theembodiments of the disclosure.

Provided herein are novel short hairpin RNA (shRNA) molecules andcompositions and kits comprising such molecules, as well as methods ofmaking and using these molecules, compositions, and kits.

As provided below in Example 1, the general molecular properties ofshRNAs that are processed into potent siRNAs by Ago2 were characterizedusing pre-miR-451 as a model molecule. As shown in Example 1 below, theAgo2-sliced siRNAs (sli-siRNAs) have the same silencing potency as theclassical Dicer-diced siRNAs (di-siRNAs), but with dramatically reducedunwanted sense strand activities. Additionally, as shown below, thepopular U6 shRNA expression promoter that was modified (U6m), but notthe H1 or U1 promoter, expressed sli-siRNAs in mammalian cells bothconstitutively and conditionally. Through lengthy analysis of thesubstrate properties of sli-siRNAs, the canonical structure ofsli-siRNAs that will produce potent sli-siRNAs was defined and isprovided herein.

siRNA molecules that have a potent on-target effect and lack off-targetactivities are highly desirable for both clinical and researchapplications. Although extensive research has been focused on thispurpose, it is still a challenge to find an siRNA that is optimized fora specific target. Many design rules, including sequence selection, basemodifications, target site accessibility, and the end thermodynamicsstability of di-siRNAs have to be applied during design in order to findan ideal siRNA (Jackson 2010; Petri 2013).

Interestingly, miR-451 uses an elegant slicing biogenesis mechanism thatinvolves Ago2, but not necessarily Dicer (Cheloufi 2010; Cifuentes 2010;Yang 2010). This mechanism can be used to design shRNAs that can beloaded onto Ago2 to be processed only by Ago2 into functional siRNAswithout sense strand activity (FIG. 1C). Ago2 acts by first nicking theshRNA substrates in the middle of the 3p to produce a long fragment(bases 1 to 30, 30 nt long; hereafter referred to as L30) and a shortfragment (bases 31 to 42, 12 nt long; hereafter referred to as 3L12).The 3′ end of L30 is then trimmed by other enzymes to produce afunctional siRNA that is capable of gene silencing (FIG. 2A-C) (Cheloufi2010; Cifuentes 2010; Yang 2010). Although pre-miR-451 and mimicsequences can be loaded into RISCs formed by all Agos, they areexclusively processed by Ago2 (Dueck 2012; Yang 2012). This mechanismcould also explain the mystery behind the potency of syn-shRNAs relatedto the length of its stems and the choice of strand used to implementanti-sense strand (Dallas 2012). This mechanism was applied to designshRNAs with short stems which were characterized as Dicer-independentand Ago2-prone processing agoshRNA (Liu 2013).

Despite published results of detailed parameters regarding miR-451biogenesis and the fact that pre-miR-451 mimic sequences have reducedsense strand activities and may avoid the competition with endogenousmiRNAs for processing machinery (Dueck 2012; Yang 2012; Liu 2013; Ma2014), the application of sli-siRNAs is still very limited compared totraditional siRNAs. One reason is the lack of general rules to designsli-siRNAs. In addition, there are no versatile vectors that arespecifically constructed to express sli-siRNAs. Furthermore, the effectsof sli-siRNAs on their targets, endogenous miRNA pathways in cells, andother response of the host immune system to their presence, must beaddressed in order for them to have a broad usage and serve as clinicaltherapeutic molecules. Detailed rules and parameters that are based onexperimental data are still lacking in order to effectively createoptimal shRNAs using a variety of shRNA expression promoters.

As set forth herein, the experiments in Example 1 below were used todefine parameters and rules that can be used to engineer optimalsynthetic shRNA molecules that can be preferentially processed by Ago2into potent siRNAs. In addition, stable and inducible U6 drivenexpression systems were developed to express optimal vector expressedshRNAs. The potential effect of these shRNAs on endogenous miRNApathways, in addition to understanding host immunoresponses to theirpresence, was also experimentally addressed as provided in Example 1.

As used herein, a synthetic version of a shRNA that is preferentiallyprocessed by Ago2, i.e., sli-siRNA, may be referred to as “agsiRNA” or“synthetic shRNA.” As used herein, an expressed version of sli-siRNA(i.e., an sli-siRNA expressed from a vector) may be referred to as“agshRNA” or “vector expressed shRNA.” The synthetic shRNA molecule andthe vector expressed shRNA molecule may comprise the canonical structureprovided in FIG. 1C. In certain embodiments, the shRNAs described hereinmay be designed to silence the expression of a target gene. In certainembodiments, silencing the expression of a target gene may includerepression and/or cleavage of a target gene.

Although the agsiRNA and agshRNA model molecules are similar to thepreviously reported model molecules, sshRNA and agoshRNA, in that theyall use Ago2 for processing and function, the major difference betweenthese new types of small RNAs and the previously reported molecules liesin how the loop is designed: sli-siRNAs use 4 nt of the antisense asloop; sshRNA used UU to link a 19 nt antisense strand with a 19 nt sensestrand; and agoshRNA used 5-7 nt universal loops (Ge 2010; Liu 2013).Although sli-siRNAs generally have similar silencing potency todi-siRNAs, sli-siRNAs have dramatically reduced sense strand activities,thus much less off-target effect. Thus, the parameters provided hereinmay be used to design exemplary synthetic shRNAs and vector expressedshRNAs that are potent RNAi triggers with reduced off-target effects.

One aspect provided herein relates to a synthetic short hairpin (shRNA)molecule comprising, consisting of, or consisting essentially of:

(a) a 5′ arm and a 3′ arm comprising:

(i) a stem region comprising 16, 17, or 18 base pairs, the base pairscomprising nucleotides from the 5′ arm paired with nucleotides from the3′ arm, and

(ii) one or more unpaired nucleotides at the 5′ terminal end of the 5′arm and one or more unpaired nucleotides at the 3′ terminal end of the3′ arm; and

(b) a loop region comprising 4 nucleotides that connects the 5′ arm tothe 3′ arm,

wherein the synthetic shRNA molecule is processed by Argonaute 2 (Ago2)in a Dicer-independent manner.

In certain embodiments, the synthetic shRNA molecule may be a chemicallysynthesized shRNA and may comprise the canonical structure shown in FIG.1C. The experimental parameters characterized in Examples 1 and 2 andprovided below may be used to design synthetic shRNA molecules that willbe preferentially processed by Ago2 into potent siRNAs used to silencethe expression of target genes. The exemplary parameters for designingsynthetic shRNAs are as follows and as detailed below in Examples 1 and2:

As used herein, the “stem region” of the synthetic shRNA molecule refersto the portion of the synthetic shRNA in which bases from the 5′ armform base pairs with nucleotides from the 3′ arm. In certainembodiments, the stem region may comprise, consist of, or consistessentially of 16, 17, or 18 base pairs. In certain preferredembodiments, the stem region is 17 base pairs in length. In certainembodiments, the base pairs are formed through pairing of nucleotidesfrom the 5′ arm with nucleotides from the 3′ arm of the synthetic shRNAmolecule. For example, in certain embodiments, when the stem region is17 base pairs in length, the 17 base pairs may be comprised of 17nucleotides from the 5′ arm paired with 17 nucleotides of the 3′ arm asshown, for example, in FIG. 1C.

As used herein, the term “complementary” can be used to describe basesthat are “fully” complementary or “generally” complementary to eachother. “Fully” complementary refers to base pairs that are comprised ofthe standard arrangement of bases in relation to their opposite pairing,such as C pairing with G and U pairing with A. These fully complementarybase pairs may also be referred to as “Watson-Crick base pairs” (i.e.,C:G and/or U:A base pairs). “Generally” complementary refers tonucleotides that form Watson-Crick base pairs in addition to nucleotidesthat may form mismatch pairs, wobble base pairs, and/or no base pairs(i.e., unpaired). As used herein, “mismatch base pair” refers to a basepair that is mismatched because the pattern of hydrogen donors andacceptors from the pair of nucleotides do not correspond (e.g., A:C,G:A, A:A, U:U, C:C, G:G). As used herein “wobble base pair” refers topairs G:U or U:G. In certain embodiments, the base pairs of the stemregion of the synthetic shRNA molecule may be formed by nucleotides thatpair through one or more Watson-Crick base pairs, one or more mismatchbase pairs, one or more unpaired bases, and/or one or more wobble basepairs.

In certain embodiments, the synthetic shRNA comprises one or moreunpaired nucleotides at the 5′ terminal end of the 5′ arm and one ormore unpaired nucleotides at the 3′ terminal end of the 3′ arm. As the5′ and 3′ terminal nucleotides do not form a base pair, a small fork isformed by the nucleotide mismatch. As discussed below, Ago2 has a muchhigher binding affinity for substrates that have an A or U at the 5′terminal end as opposed to a C or G. In certain embodiments, thesynthetic shRNA molecules herein may comprise one unpaired nucleotide atthe 5′ terminal end of the 5′ arm that is selected from an A or a U. Incertain embodiments, the one or more unpaired nucleotides at the 5′terminal end of the 5′ arm may be two As. In certain embodiments, theone or more unpaired nucleotides at the 5′ terminal end of the 5′ armmay be one U and one A, wherein the A is positioned 5′ relative to theU.

In certain embodiments, the synthetic shRNA molecules herein maycomprise one or more unpaired nucleotides at the 5′ terminal end of the5 arm. In certain embodiments, the synthetic shRNA molecule may compriseone unpaired nucleotide at the 5′ terminal end of the 5′ arm that isnon-phosphorylated. Phosphorylation of the 5′ end may increase thepotency of Dicer sliced siRNAs and is required for siRNA loading(Schwarz 2003). However, as shown below, no difference was observed inpotency of synthetic shRNA molecules synthesized with or withoutphosphorylation of the 5′ terminal end. In certain embodiments, thesynthetic shRNA molecule may comprise one unpaired nucleotide at the 5′terminal end of the 5′ arm that is phosphorylated.

In certain embodiments, the synthetic shRNA may comprise one or moreunpaired nucleotides at the 3′ terminal end of the 3′ arm. In certainembodiments, the one or more unpaired nucleotides at the 3′ terminal endof the 3′ arm may be selected from the group consisting of adeoxythymidine nucleotide (dT), a dideoxycytidine (ddC) nucleotide, anda C. In certain preferred embodiments, the one or more unpairednucleotides at the 3′ terminal end of the 3′ arm is one C. In certainembodiments, the one or more unpaired nucleotides at the 3′ terminal endof the 3′ arm are two deoxythymidine nucleotides (i.e., dTdT) and one C,wherein the C is positioned 5′ relative to the two dTdTs. In certainembodiments, the one or more unpaired nucleotides at the 3′ terminal endof the 3′ arm is one unpaired dideoxycytidine nucleotide (i.e, ddC). Asdiscussed below, the ddC modification can prevent degradation from the3′ end, which would be beneficial to the design of synthetic shRNAs toincrease its stability.

As used herein, the “loop region” refers to the portion of the syntheticshRNA that connects the 5′ arm to the 3′ arm. In certain embodiments,the loop region of the synthetic shRNA comprises, consists of, orconsists essentially of 3, 4, 5, or 6 nucleotides. In certain preferredembodiments, the loop region of the synthetic shRNA consists of orconsists essentially of 4 nucleotides. As shown below in Example 1, theloop sequence and length of the synthetic shRNA may influence thesilencing potential of the mature siRNA generated from the syntheticshRNA. In certain preferred embodiments, the loop region of thesynthetic shRNA is 4 nucleotides long and connects the 5′ arm to the 3′arm.

In certain embodiments, the synthetic shRNA molecule may comprise,consist of or consist essentially of 36, 37, 38, 39, 40, 41, 42, 43, 44,or 45 nucleotides (nts). In certain of these embodiments, the syntheticshRNA molecule may consist of or consist essentially of 40 nts. When thesynthetic shRNA molecule is 40 nts, the first nucleotide positioned atthe 5′ terminal end of the 5′ arm is designated as position (p) p1 andthe last nucleotide positioned at the 3′ terminal end of the 3′ arm isdesignated as p40 (see e.g., FIG. 1C).

In certain embodiments, an antisense region of the synthetic shRNA maycomprise, consist of, or consist essentially of the 5′ arm and the loopregion of the synthetic shRNA molecule and a sense region may comprise,consist of, or consist essentially of the 3′ arm of the synthetic shRNAmolecule. In certain embodiments, the antisense region is the guidestrand and the sense region is the passenger strand. The antisenseregion of the synthetic shRNA molecule may comprise a seed region, acentral region, a 3′ supplementary region and a tail region (see e.g.,FIG. 1C). In certain embodiments, when the synthetic shRNA is 40 nts,the antisense region may comprise a nucleotide sequence of a seed regioncomprising nucleotides p2-p8, a nucleotide sequence of a central regioncomprising nucleotides p9-p12, a nucleotide sequence of a 3′supplementary region comprising nucleotides p13-p17 and a nucleotidesequence of a tail region comprising nucleotides p18-p22 (see e.g., FIG.1C). In certain embodiments, the sense region may be fully complementaryor generally complementary to a portion of the antisense region. Incertain embodiments, the antisense region may comprise a nucleotidesequence that is fully or generally complementary to a target nucleotidesequence. In certain embodiments, the target nucleotide sequence maycomprise a portion of a nucleotide sequence of a target gene. In certainembodiments, the target gene may be any gene that is being targeted forgene silencing through RNA interference by the mature siRNA that resultsfrom Ago2 and other enzyme processing of the synthetic shRNA. In certainembodiments, the target nucleotide sequence may be a sequence of aportion of messenger RNA (mRNA).

As shown in Example 2 below, sli-siRNAs have a much higher tolerance formismatch targets when the mismatch is located in the 3′ supplementaryregion versus the seed region. In certain embodiments, the nucleotidesequence of the seed region may be fully complementary to a portion ofthe target nucleotide sequence. In certain embodiments, the nucleotidesequence of the seed region may be fully complementary to a portion ofthe target sequence, and the nucleotide sequence of the 3′ supplementaryregion may be generally complementary to a portion of the targetsequence. In these embodiments, the nucleotide sequence of the portionof the target sequence may form one, two, three, four, or five,mismatched base pairs with the 3′ supplementary region. In certainembodiments, the nucleotide sequence of the seed region may be generallycomplementary to a portion of the target nucleotide sequence. In certainpreferred embodiments, the nucleotide sequence of the central region maybe fully complementary to a portion of the target nucleotide sequence.In certain embodiments, the nucleotide sequence of the central regionmay be generally complementary to a portion of the target nucleotidesequence. In certain preferred embodiments, the nucleotide sequence ofthe 3′ supplementary region may be fully or generally complementary to aportion of the target nucleotide sequence. In certain preferredembodiments, the nucleotide sequence of the tail region may be fullycomplementary to a portion of the target nucleotide sequence. In certainembodiments, the nucleotide sequence of the tail region may be generallycomplementary to a portion of the target nucleotide sequence.

In certain embodiments, when the synthetic shRNA molecule comprises 40nts (i.e., p1-p40) and the stem region comprises 17 base pairs, the basepairs of the stem region comprise nucleotides p2-p18 of the 5′ arm basepaired with nucleotides p39-p23 of the 3′ arm, respectively (i.e.,p2:p39, p3:p38, p4:p37, p5:p36, p6:p35, p7:p34, p8:p33, p9:p32, p10:p31,p11:p30, p12:p29, p13:p28, p14:p27, p15:p26, p16:p25, p17:p24, andp18:p23) as illustrated in FIG. 1C. In certain preferred embodiments,the base pairs formed between nucleotides p2-p18 and nucleotidesp39-p23, respectively, may be fully complementary forming allWatson-Crick base pairs. In other preferred embodiments, the base pairsformed between nucleotides p2-p18 and nucleotides p39-p23 may begenerally complementary, wherein the base pairs formed betweennucleotides p2-p17 and nucleotides p39-p24 are Watson-Crick base pairsand the base pair formed between p18 and p23 is a wobble base pair. Incertain embodiments, the base pairs formed between nucleotides p2-p18and nucleotides p39-p23 may be generally complementary, wherein the basepairs p3:p38, p4:p39, p5:p36, p8:p33, p9:p32, p10:p31, p11:p30, p12:p29,p13:p28, p14:p27, p15:p26, p16:p25, p27:p24 are Watson Crick base pairsand the base pairs p2:p39, p6:p35, p7:p34, and p18:p23 may be selectedfrom the group consisting of a Watson-Crick base pair, a mismatch basepair, a wobble base pair, and an unpaired base pair.

In certain embodiments, the synthetic shRNA molecule has the ability tobypass the Dicer processing step and be specifically processed by Ago2.The specific production of the synthetic shRNA molecules herein by Ago2may limit their incorporation into other non-slicing Argonaute familymembers (Ago1, Ago3, and Ago4 for mammals) formed RISCs; therefore, itis possible that the synthetic shRNAs provided herein may also reduceRNAi off-target effects caused by siRNAs loading into other Argonautes(Petri 2011). Ago2 acts by first nicking the synthetic shRNA substratesin the middle of the 3p to produce a long fragment and a short fragment.In certain embodiments, the Ago2 nick site may be located near themiddle of the 3′ arm of the synthetic shRNA. In certain embodiments,when the synthetic shRNA molecule is 40 nts, the Ago nick site may belocated between nucleotides p30 and p31.

In certain preferred embodiments, a synthetic shRNA may comprise:

(a) a 5′ arm and a 3′ arm comprising:

(i) a stem region that is 17 base pairs, the base pairs comprisingnucleotides from the 5′ arm paired with nucleotides from the 3′ arm,wherein the base pairs formed between nucleotides p2-p18 from the 5′ armand nucleotides p39-p23 from the 3′ arm may be generally complementary,the base pairs formed between nucleotides p2-p17 and nucleotides p39-p24are Watson-Crick base pairs and the base pair formed between p18 and p23is a wobble base pair, and

(ii) one unpaired nucleotide at the 5′ terminal end of the 5′ arm thatis not phosphorylated and is selected from the group consisting of an Aand a U, and one unpaired nucleotide at the 3′ terminal end of the 3′arm that is selected from the group consisting of a C or adideoxycytidine nucleotide (ddC); and

(b) a loop region comprising 4 nucleotides that connects the 5′ arm tothe 3′ arm,

wherein the shRNA molecule is processed by Argonaute 2 (Ago2) in aDicer-independent manner.

Another aspect provided herein relates to a vector expressed shorthairpin (shRNA) molecule comprising, consisting of or consistingessentially of:

(a) a 5′ arm and a 3′ arm comprising:

(i) a stem region comprising 16, 17, or 18 base pairs, the base pairscomprising nucleotides from the 5′ arm paired with nucleotides from the3′ arm, and

(ii) one or more unpaired nucleotides at the 5′ terminal end of the 5′arm and one or more unpaired nucleotides at the 3′ terminal end of the3′ arm; and

(b) a loop region comprising 4 nucleotides that connects the 5′ arm tothe 3′ arm,

wherein the vector expressed shRNA molecule is processed by Argonaute 2(Ago2) in a Dicer-independent manner.

In certain embodiments, the vector expressed shRNA molecule may be ashRNA that is expressed using a DNA vector system that encodes thevector expressed shRNA molecule. Similar to the synthetic shRNAmolecules described above, the vector expressed shRNA moleculesdescribed herein may be potent RNAi triggers and can be used to silencethe expression of target genes. Additionally, in certain embodiments,the vector expressed shRNA molecules may comprise the canonicalstructure illustrated in FIG. 1C. In certain embodiments, syntheticshRNA molecules may be any of the shRNA molecules as disclosed herein.The experimental parameters characterized in Examples 1 and 2 andprovided herein may be used to design vector expressed shRNA moleculesthat will be preferentially processed by Ago2 into potent siRNAs. Theexemplary parameters for designing vector expressed shRNAs are asfollows:

As used herein, the “stem region” of the vector expressed shRNA moleculerefers to the portion of the synthetic shRNA in which bases from the 5′arm form base pairs with nucleotides from the 3′ arm. In certainembodiments, the stem region may comprise, consist of, or consistessentially of 16, 17, or 18 base pairs. In preferred embodiments, thestem region is 17 base pairs in length. In certain embodiments, the basepairs are formed through pairing of nucleotides from the 5′ arm withnucleotides from the 3′ arm of the vector expressed shRNA molecule. Forexample, in certain embodiments, when the stem region is 17 base pairsin length, the 17 base pairs may be comprised of 17 nucleotides from the5′ arm paired with 17 nucleotides of the 3′ arm.

As used herein, the term “complementary” can be used to describe basesthat are “fully” complementary or “generally” complementary to eachother as described above. In certain embodiments, the base pairs of thestem region of the vector expressed shRNA molecule may be formed bynucleotides that pair through one or more Watson-Crick base pairs, oneor more mismatch base pairs, one or more unpaired bases, and/or one ormore wobble base pairs.

In certain embodiments, the vector expressed shRNA comprises one or moreunpaired nucleotides at the 5′ terminal end of the 5′ arm and one ormore unpaired nucleotides at the 3′ terminal end of the 3′ arm. As the5′ and 3′ terminal nucleotides do not form a base pair, a small fork isformed by the nucleotide mismatch. In certain preferred embodiments, thevector expressed shRNA molecules herein may comprise one unpairednucleotide at the 5′ terminal end of the 5′ arm that is an A.

As used herein, the “loop region” refers to the portion of the loopregion of the vector expressed shRNA comprising, consisting of, orconsisting essentially of 3, 4, 5, or 6 nucleotides. As shown below inExample 1, the loop sequence and length of the vector expressed shRNAmay influence the silencing potential of the mature siRNA generated fromthe vector expressed shRNA. In preferred embodiments, the loop region ofthe vector expressed shRNA is 4 nucleotides long and connects the 5′ armto the 3′ arm.

In certain embodiments, the vector expressed shRNA molecule maycomprise, consist of or consist essentially of 36, 37, 38, 39, 40, 41,42, 43, 44, or 45 nucleotides. In certain of these embodiments, thesynthetic shRNA molecule may consist of or consist essentially of 40nts. When the preferred vector expressed shRNA molecule is 40 nts, thefirst nucleotide positioned at the 5′ terminal end of the 5′ arm isdesignated as position p1 and the last nucleotide positioned at the 3′terminal end of the 3′ arm is designated as p40 (see e.g., FIG. 1C).

In certain embodiments, an antisense region of the vector expressedshRNA may comprise, consist of, or consist essentially of the 5′ arm andthe loop region of the vector expressed shRNA molecule and a senseregion may comprise, consist of, or consist essentially of the 3′ arm ofthe vector expressed shRNA molecule. In certain embodiments, theantisense region is the guide strand and the sense region is thepassenger strand. The antisense region of the vector expressed shRNAmolecule may comprise a nucleotide sequence of a seed region, anucleotide sequence of a central region, a nucleotide sequence of a 3′supplementary region and a nucleotide sequence of a tail region (seee.g., FIG. 1C). In certain embodiments, when the vector expressed shRNAis 40 nts, the antisense region may comprise a nucleotide sequence of aseed region comprising nucleotides p2-p8, a nucleotide sequence of acentral region comprising nucleotides p9-p12, a nucleotide sequence of a3′ supplementary region comprising nucleotides p13-p17 and a nucleotidesequence of a tail region comprising nucleotides p18-p22 (see e.g., FIG.1C). In certain embodiments, the sense region may be fully complementaryor generally complementary to a portion of the antisense region. Incertain embodiments, the antisense region may comprise a nucleotidesequence that is fully or generally complementary to a target nucleotidesequence. In certain embodiments, the target nucleotide sequence maycomprise a portion of a nucleotide sequence of a target gene. In certainembodiments, the target gene may be any gene that is being targeted forgene silencing through RNA interference by the mature siRNA that resultsfrom Ago2 and other enzyme processing of the vector expressed shRNA. Incertain embodiments, the target nucleotide sequence may be a sequence ofa portion of messenger RNA (mRNA). For example, in certain embodiments,the target nucleotide sequence may be a target RNA sequence comprising amessage RNA sequence of the target gene.

In certain embodiments, the nucleotide sequence of the seed region maybe fully complementary to a portion of the target nucleotide sequence.In certain embodiments, the nucleotide sequence of the seed region maybe fully complementary to a portion of the target sequence, and thenucleotide sequence of the 3′ supplementary region may be generallycomplementary to a portion of the target sequence. In these embodiments,the nucleotide sequence of the portion of the target sequence may formone, two, three, four, or five, mismatched base pairs with the 3′supplementary region. In certain preferred embodiments, the nucleotidesequence of the seed region may be fully complementary to a portion ofthe target nucleotide sequence. In certain embodiments, the nucleotidesequence of the seed region may be generally complementary to a portionof the target nucleotide sequence. In certain preferred embodiments, thenucleotide sequence of the central region may be fully complementary toa portion of the target nucleotide sequence. In certain embodiments, thenucleotide sequence of the central region may be generally complementaryto a portion of the target nucleotide sequence. In certain preferredembodiments, the nucleotide sequence of the 3′ supplementary region maybe fully or generally complementary to a portion of the targetnucleotide sequence. In certain preferred embodiments, the nucleotidesequence of the tail region may be fully complementary to a portion ofthe target nucleotide sequence. In certain embodiments, the nucleotidesequence of the tail region may be generally complementary to a portionof the target nucleotide sequence.

In certain embodiments, when the vector expressed shRNA moleculecomprises 40 nts (i.e., p1-p40) and the stem region comprises 17 basepairs, the base pairs of the stem region may comprise nucleotides p2-p18of the 5′ arm base paired with nucleotides p39-p23 of the 3′ arm,respectively (i.e., p2:p39, p3:p38, p4:p37, p5:p36, p6:p35, p7:p34,p8:p33, p9:p32, p10:p31, p11:p30, p12:p29, p13:p28, p14:p27, p15:p26,p16:p25, p17:p24, and p18:p23) as illustrated in FIG. 1C. In certainpreferred embodiments, the base pairs formed between nucleotides p2-p18and nucleotides p39-p23, respectively, may be fully complementaryforming all Watson-Crick base pairs. In other preferred embodiments, thebase pairs formed between nucleotides p2-p18 and nucleotides p39-p23 maybe generally complementary, wherein the base pairs formed betweennucleotides p2-p17 and nucleotides p39-p24 are Watson-Crick base pairsand the base pair formed between p18 and p23 is a wobble base pair. Incertain embodiments, the base pairs formed between nucleotides p2-p18and nucleotides p39-p23 may be generally complementary, wherein the basepairs p3:p38, p4:p39, p5:p36, p8:p33, p9:p32, p10:p31, p11:p30, p12:p29,p13:p28, p14:p27, p15:p26, p16:p25, p27:p24 are Watson Crick base pairsand the base pairs p2:p39, p6:p35, p7:p34, and p18:p23 may be selectedfrom the group consisting of a Watson-Crick base pair, a mismatch basepair, a wobble base pair, and an unpaired base pair.

In certain embodiments, the vector expressed shRNA molecule has theability to bypass the Dicer processing step and be specificallyprocessed by Ago2 as described herein. In certain embodiments, the Ago2nick site may be located near the middle of the 3′ arm of the vectorexpressed shRNA. In certain embodiments, when the vector expressed shRNAmolecule is 40 nts, the Ago nick site may be located between nucleotidesp30 and p31.

In certain embodiments, the vector expressed shRNA may be expressed by avector as described herein.

In certain preferred embodiments, a vector expressed shRNA may comprise:

(a) a 5′ arm and a 3′ arm comprising:

(i) a stem region that is 17 base pairs, the base pairs comprisingnucleotides from the 5′ arm paired with nucleotides from the 3′ arm,wherein the base pairs formed between nucleotides p2-p18 from the 5′ armand nucleotides p39-p23 from the 3′ arm may be generally complementary,the base pairs formed between nucleotides p2-p17 and nucleotides p39-p24are Watson-Crick base pairs and the base pair formed between p18 and p23is a wobble base pair, and

(ii) one unpaired nucleotide at the 5′ terminal end of the 5′ arm thatis an A and one unpaired nucleotide at the 3′ terminal end of the 3′ armthat is a C; and

(b) a loop region comprising 4 nucleotides that connects the 5′ arm tothe 3′ arm,

wherein the synthetic shRNA molecule is processed by Ago2 in aDicer-independent manner.

Another aspect provided herein relates to a vector comprising anucleotide sequence encoding one or more vector expressed shRNAmolecules comprising, consisting of or consisting essentially of:

(a) a 5′ arm and a 3′ arm comprising:

(i) a stem region comprising 16, 17, or 18 base pairs, the base pairscomprising nucleotides from the 5′ arm paired with nucleotides from the3′ arm, and

(ii) one or more unpaired nucleotides at the 5′ terminal end of the 5′arm and one or more unpaired nucleotides at the 3′ terminal end of the3′ arm; and

(b) a loop region comprising 4 nucleotides that connects the 5′ arm tothe 3′ arm,

wherein the vector expressed shRNA molecule is processed by Argonaute 2(Ago2) in a Dicer-independent manner.

In certain embodiments, the vector may encode any one or more of thevector expressed shRNA molecules as described herein and provided inExamples 1 and 2 below. In certain embodiments, the vector may encodeone, two, three, four, five, six, seven, eight, nine, or ten vectorexpressed shRNA. In certain embodiments, the vector comprises a DNAnucleotide sequence encoding the one or more vector expressed shRNA. Incertain embodiments, the vector may encode any one or more of a vectorexpressed shRNA molecule designed using the parameters for designingvector expressed shRNA molecules that are provided herein.

As shown in Example 1, the U6 expression promoter was modified toexpress synthetic shRNAs in mammalian cells both constitutively andconditionally and certain synthetic shRNAs were shown to be correctlyprocessed to repress the expression of their target genes. The design ofthe constitutive and inducible vectors described in Example 1 was basedon a previously reported synthetic shRNA expression vector that containsthe U6 promoter as described in Aagaard 2007, the subject matter ofwhich is hereby incorporated by reference as if fully set forth herein.In certain embodiments, the vector may be a conditional expressionvector comprising a U6 promoter to drive expression of the vectorexpressed shRNA molecule. In certain embodiments, the vector may be aninducible expression vector that may be designed by mutating a portionof the U6 promoter sequence into a TetR binding sequence (i.e., U6TO) asdescribed in Aagaard 2007. In certain embodiments, the vector may be aninducible expression vector comprising a doxycycline [dox]-inducible U6(U6TO) promoter to drive expression of the vector expressed shRNAmolecule. In certain embodiments, the U6 sequence may be modified andmay be used to express the synthetic shRNA. For example, in certainembodiments, the modified U6 promoter sequence may comprise the U6+MCSsequence (i.e., SEQ ID NO: 143) or the U6TO+MCS sequence (SEQ ID NO:144).

In certain embodiments, the vector that is used to express the vectorexpressed shRNA may be any vector known to one of ordinary skill in theart that can be used to express synthetic shRNAs. For example, thevector may be a retroviral vector. In certain embodiments, the vectormay be a lentivirus vector. In certain embodiments, the lentivirusvector may comprise an expression cassette comprising a U6 promoter(e.g., a modified U6 promoter) and a nucleotide sequence encoding avector expressed shRNA. In certain embodiments, the vector may be anadenovirus. In certain embodiments, the vector may be anadeno-associated virus.

Another aspect provided herein relates to a cell comprising a vectorcomprising a nucleotide sequence encoding one or more vector expressedshRNA molecules comprising, consisting of or consisting essentially of:

(a) a 5′ arm and a 3′ arm comprising:

(i) a stem region comprising 16, 17, or 18 base pairs, the base pairscomprising nucleotides from the 5′ arm paired with nucleotides from the3′ arm, and

(ii) one or more unpaired nucleotides at the 5′ terminal end of the 5′arm and one or more unpaired nucleotides at the 3′ terminal end of the3′ arm; and

(b) a loop region comprising 4 nucleotides that connects the 5′ arm tothe 3′ arm,

wherein the vector expressed shRNA molecule is processed by Argonaute 2(Ago2) in a Dicer-independent manner.

In certain embodiments, the vector and the one more vector expressedshRNA molecules are the same as described herein. In certainembodiments, the cell may comprise one or more vectors.

In certain embodiments, the cell may be a bacteria cell. In certainembodiments, the cell may be a mammalian cell, such as a human cell.

In certain embodiments, the cell may be infected with a virus comprisinga vector as described herein. For example, in certain embodiments, thecell may be infected with a lentivirus comprising a vector as describedherein.

Another aspect provided herein relates to a method of designing asynthetic shRNA molecule or a vector expressed shRNA molecule comprisingdesigning the synthetic shRNA molecule or the vector expressed shRNAmolecule as described herein.

In certain embodiments, the synthetic shRNA molecule or vector expressedshRNA molecule may be designed using the parameters as provided herein.In certain embodiments, the method may further comprise chemicallysynthesizing the synthetic shRNA molecule.

In certain embodiments, the method of designing a synthetic shRNAmolecule and/or a vector expressed shRNA molecule provides for thesynthesis and/or expression of synthetic shRNA molecules that produceless unwanted passenger strands, which results in the reduction ofoff-target effects and lower toxicity to the cell. The molecularstructure of the synthetic and vector expressed shRNA affords that thesesiRNAs will be less toxic than their previous generations since theirshort lengths will limit their ability to stimulate innate immuneresponses. Additionally, these optimally designed synthetic shRNAmolecules retain their potent inhibiting activity while reducing theproduction of unwanted passenger strands which causes off-targeteffects. Further, due to their short length, these synthetic and vectorexpressed shRNA molecules are less toxic to the cell because they havelimited ability to stimulate the innate immune response. Moreover, theyare cheap and easy to produce due to their small size.

In certain embodiments, the methods provided herein can be used todesign synthetic shRNA molecules or vector expressed shRNAs usingantisense strand selection software.

Another aspect provided herein relates to a method of silencingexpression of a target nucleotide sequence comprising:

-   -   obtaining a sample comprising the target nucleotide sequence,        and    -   providing any one or more of the synthetic shRNA molecules        described herein to the sample.

Another aspect provided herein relates to a method of silencingexpression of a target nucleotide sequence comprising:

-   -   obtaining a sample comprising the target nucleotide sequence,        and    -   providing a vector encoding any one or more of the vector        expressed shRNA molecules described herein to the sample.

In certain embodiments, the synthetic shRNA molecules and/or vectorexpressed shRNA molecules are the same as described herein.

In certain embodiments, the method of silencing expression of a targetnucleotide sequence using the synthetic shRNA molecules described hereinresults in a reduced production of unwanted sense strand and off-targeteffects. The synthetic shRNA molecules and/or vector expressed shRNAmolecules may be used to target molecules that are part of a cellularregulation pathway in order to determine the effect that suppression ofthe target molecule in relation to other molecules has on the pathway.In this sense, the synthetic shRNA molecules and/or vector expressedshRNA molecules may be used in research methods for determining themechanism of action in signaling pathways for drug discovery or for thediscovery of other research tools used for in vivo or in vitro assays.In other embodiments, the synthetic shRNA molecules and/or vectorexpressed shRNA molecules may be designed to suppress expression of atarget gene or variant thereof which is associated with cancer orresistance to chemotherapy (or other cancer treatment). In certainembodiments, the vectors encoding the vector expressed shRNA as usedherein may permit transgenic expression of many kinds of individualshort sequences that bind to Ago2 that can be used to study theirbiological functions. The exemplary vector expressed shRNA system hasthe ability to also allow researchers to express short sequences inDicer knockout mouse or cell lines and can provide a tool for performinggenetic rescues experiments for some of the small noncoding RNAs.

Another aspect provided herein relates to a method of treating a subjecthaving a disease or condition comprising administering a therapeuticallyeffective amount of one or more of any of the synthetic shRNA moleculesdescribed herein to the subject.

Another aspect provided herein relates to a method of treating a subjecthaving a disease or condition comprising administering a vectorcomprising a nucleotide sequence encoding one or more vector expressedshRNA molecules to the subject. In certain embodiments, atherapeutically effective amount of one or more of any of the vectorexpressed shRNA molecules may be expressed by the vector.

In certain embodiments, the disease or condition may be any disease orcondition that can be manipulated by knockdown (e.g., silencing) of aparticular gene. In certain embodiments, the disease or condition may becancer. In certain embodiments, the disease or condition may be humanimmunodeficiency virus (HIV). In certain embodiments, the disease orcondition may be hepatitis C virus (HCV).

In some embodiments, the synthetic shRNA molecules, vector expressedshRNA molecules, and/or vectors comprising a nucleotide sequenceencoding one or more vector expressed shRNA molecules (i.e., vectorsencoding shRNA) may be used as a therapeutic agent alone, conjugated toone or more additional delivery, diagnostic or therapeutic agents.

The terms “treat,” “treating,” or “treatment” as used herein withregards to a disease or condition refers to preventing the disease orcondition, slowing the onset or rate of development of the disease orcondition, reducing the risk of developing the disease or condition,preventing or delaying the development of symptoms associated with thedisease or condition, reducing or ending symptoms associated with thedisease or condition, generating a complete or partial regression of thedisease or condition, or some combination thereof.

According to some embodiments, the synthetic shRNA molecules, vectorexpressed shRNA molecules and/or vectors encoding synthetic shRNA may bepart of a pharmaceutical composition. Such a pharmaceutical compositionmay include one or more of the synthetic shRNA molecules, vectorexpressed shRNA molecules and/or vector encoding synthetic shRNA and apharmaceutically acceptable carrier. A “pharmaceutically acceptablecarrier” as used herein refers to a pharmaceutically acceptablematerial, composition, or vehicle that is involved in carrying ortransporting a compound of interest from one tissue, organ, or portionof the body to another tissue, organ, or portion of the body. Such acarrier may comprise, for example, a liquid, solid, or semi-solidfiller, solvent, surfactant, diluent, excipient, adjuvant, binder,buffer, dissolution aid, solvent, encapsulating material, sequesteringagent, dispersing agent, preservative, lubricant, disintegrant,thickener, emulsifier, antimicrobial agent, antioxidant, stabilizingagent, coloring agent, or some combination thereof.

Each component of the carrier is “pharmaceutically acceptable” in thatit must be compatible with the other ingredients of the composition andmust be suitable for contact with any tissue, organ, or portion of thebody that it may encounter, meaning that it must not carry a risk oftoxicity, irritation, allergic response, immunogenicity, or any othercomplication that excessively outweighs its therapeutic benefits.

Some examples of materials which can serve aspharmaceutically-acceptable carriers include: (1) sugars, such aslactose, glucose and sucrose; (2) starches, such as corn starch andpotato starch; (3) cellulose, and its derivatives, such as sodiumcarboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4)powdered tragacanth; (5) malt; (6) natural polymers such as gelatin,collagen, fibrin, fibrinogen, laminin, decorin, hyaluronan, alginate andchitosan; (7) talc; (8) excipients, such as cocoa butter and suppositorywaxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil,sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such aspropylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol andpolyethylene glycol; (12) esters, such as trimethylene carbonate, ethyloleate and ethyl laurate; (13) agar; (14) buffering agents, such asmagnesium hydroxide and aluminum hydroxide; (15) alginic acid (oralginate); (16) pyrogen-free water; (17) isotonic saline; (18) Ringer'ssolution; (19) alcohol, such as ethyl alcohol and propane alcohol; (20)phosphate buffer solutions; (21) thermoplastics, such as polylacticacid, polyglycolic acid, (22) polyesters, such as polycaprolactone; (23)self-assembling peptides; and (24) other non-toxic compatible substancesemployed in pharmaceutical formulations such as acetone.

The pharmaceutical compositions may contain pharmaceutically acceptableauxiliary substances as required to approximate physiological conditionssuch as pH adjusting and buffering agents, toxicity adjusting agents andthe like, for example, sodium acetate, sodium chloride, potassiumchloride, calcium chloride, sodium lactate and the like.

In one embodiment, the pharmaceutically acceptable carrier is an aqueouscarrier, e.g. buffered saline and the like. In certain embodiments, thepharmaceutically acceptable carrier is a polar solvent, e.g. acetone andalcohol.

The concentration of synthetic shRNA molecules, vector expressed shRNAmolecules and/or vectors encoding synthetic shRNA in the formulationsprovided herein can vary widely, and will be selected primarily based onfluid volumes, viscosities, organ size, body weight and the like inaccordance with the particular mode of administration selected and thebiological system's needs.

Synthetic shRNA molecules, vector expressed shRNA molecules, vectorsencoding synthetic shRNA, and/or pharmaceutical compositions thereof canbe administered to a biological system by any administration route knownin the art, including without limitation, oral, enteral, buccal, nasal,topical, rectal, vaginal, aerosol, transmucosal, epidermal, transdermal,dermal, ophthalmic, pulmonary, subcutaneous, and/or parenteraladministration. The pharmaceutical compositions can be administered in avariety of unit dosage forms depending upon the method ofadministration. In one embodiment, the synthetic shRNA molecule, vectorexpressed shRNA molecule, vector encoding synthetic shRNA, and/orpharmaceutical composition thereof is administered parenterally. Aparenteral administration refers to an administration route thattypically relates to injection which includes but is not limited tointravenous, intramuscular, intraarterial, intrathecal, intracapsular,intraorbital, intra cardiac, intradermal, intraperitoneal,transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular,subarachnoid, intraspinal, and/or intrasternal injection and/orinfusion.

In some embodiments, the synthetic shRNA molecules, vector expressingsynthetic shRNA molecules, and/or vectors encoding synthetic shRNA maybe administered with a pharmaceutically effective carrier that allowsthe synthetic shRNA molecules and/or vectors to be delivered locally orsystemically to one or more target cells (i.e., virally infected cellsor cancer cells) or target organs by one or more suitable deliverymethods known in the art including, but not limited to, viral delivery,liposomal delivery, nanoparticle delivery, targeted delivery (e.g.,using an antibody, aptamer or other targeting molecule to facilitatedelivery), direct administration into target organs, systemic injectionof synthetic shRNA molecules and/or vectors, and eukaryotictranscription plasmid delivery to produce vector expressed shRNA insideof the target cells.

Synthetic shRNA molecules, vector expressing synthetic shRNA molecules,vectors encoding synthetic shRNA, and/or pharmaceutical compositionsthereof can be given to a subject in the form of formulations orpreparations suitable for each administration route. The formulationsuseful in the methods of the invention include one or more syntheticshRNA molecules, vector expressing synthetic shRNA molecules, vectorsencoding synthetic shRNA, and/or one or more pharmaceutically acceptablecarriers therefor, and optionally other therapeutic ingredients. Theformulations may conveniently be presented in unit dosage form and maybe prepared by any methods well known in the art of pharmacy. The amountof active ingredient which can be combined with a carrier material toproduce a single dosage form will vary depending upon the subject beingtreated and the particular mode of administration. The amount of asynthetic shRNA molecule and/or vector which can be combined with acarrier material to produce a pharmaceutically effective dose willgenerally be that amount of a synthetic shRNA molecule and/or vectorwhich produces a therapeutic effect.

In one embodiment of the invention, a synthetic shRNA molecule, vectorexpressed shRNA molecule, and/or vector encoding synthetic shRNA may bedelivered to a disease or infection site in a therapeutically effectivedose. A “therapeutically effective amount” or a “therapeuticallyeffective dose” is an amount of a synthetic shRNA molecule, vectorexpressed shRNA molecule, and/or vector encoding synthetic shRNA thatproduces a desired therapeutic effect in a subject, such as preventingor treating a target condition or alleviating symptoms associated withthe condition. The most effective results in terms of efficacy oftreatment in a given subject will vary depending upon a variety offactors, including but not limited to the characteristics of thesynthetic shRNA molecule, the physiological condition of the subject(including age, sex, disease type and stage, general physical condition,responsiveness to a given dosage, and type of medication), the nature ofthe pharmaceutically acceptable carrier or carriers in the formulation,and the route of administration. One skilled in the clinical andpharmacological arts will be able to determine a therapeuticallyeffective amount through routine experimentation, namely by monitoring asubject's response to administration of a compound and adjusting thedosage accordingly. For additional guidance, see Remington: The Scienceand Practice of Pharmacy 21^(st) Edition, Univ. of Sciences inPhiladelphia (USIP), Lippincott Williams & Wilkins, Philadelphia, Pa.,2005.

Another aspect provided herein relates to a kit comprising one or moreof the synthetic shRNA molecules and/or one or more of the vectorexpressed shRNA molecules described herein or compositions orformulations thereof. Other kits may comprise one or more vectorscomprising a nucleotide sequence encoding the one or more vectorexpressed shRNA molecules as described herein. In certain embodiments,the one or more synthetic shRNA molecules and/or one or more vectorexpressed shRNA molecules in the kits may be used for silencingexpression of a target nucleotide sequence. In certain embodiments, thekit may be used as a research tool to investigate the effect ofsilencing the expression of the target nucleotide sequence by the one ormore synthetic shRNA molecules and/or one or more vector expressed shRNAmolecules.

The term “about” as used herein means within 5% or 10% of a stated valueor a range of values.

The following examples are intended to illustrate various embodiments ofthe invention. As such, the specific embodiments discussed are not to beconstrued as limitations on the scope of the invention. It will beapparent to one skilled in the art that various equivalents, changes,and modifications may be made without departing from the scope ofinvention, and it is understood that such equivalent embodiments are tobe included herein. Further, all references cited in the disclosure arehereby incorporated by reference in their entirety, as if fully setforth herein.

EXAMPLES Example 1 Molecular Properties, Functional Mechanisms, andApplications of Ago2-sliced siRNAs

The general sequence parameters that can be used to design sli-siRNAsthat are preferentially processed by Ago2 into potent siRNAs wereexperimentally characterized and defined as provided in this Example. Adetailed characterization of the substrate properties of sli-siRNAs wasperformed, and a canonical structure of a synthetic shRNA called“agsiRNA” and the expressed version of sli-siRNA (i.e., vector expressedshRNA) called “agshRNA” was defined (see FIG. 1C). Vectors with theconstitutive or inducible U6 promoter that can express sli-siRNAs inmammalian cells were built where the sli-siRNAs can be correctlyprocessed to repress target genes. Additionally, as provided below, as aproof of principle for potential applications of sli-siRNAs in vivo, theexpression of one Ago2 shRNA-1148 in HCT-116 colon cancer cells knockeddown RRM2 expression and reduced the proliferation and invasiveness ofthe cells. As such, the structural parameters for designing andexpressing sli-siRNAs that are as potent as di-siRNAs are provided belowcan be used to effectively create optimal sli-siRNAs that can beprocessed into potent siRNAs.

Results

Define canonical sli-siRNA. To characterize the structural properties ofpre-miR-451 that are required for processing into the mature miR-451 byAgo2, all documented pre-miR-451 sequences from 18 species in miRBase 19were aligned and it was discovered that pre-miR-451 sequences werehighly conserved in 17 of the 18 species. Among all species, the 35thbase (p35) was almost equally a C, U, or G, so it could form a perfectGC pair, or GU wobble, or mismatch with the G at p6, respectively,indicating that flexibility for this base pairing may have beenmaintained during evolution by an unknown selection mechanism (FIGS. 3,4A, 4B, 4C, and 5). It was observed that pre-miR-451 was 42 nt long, andcould be expressed by a RNA pol III promoter if the last two pre-miRNAnt were replaced with an UU. Therefore, pre-miR-451 that lacks the lasttwo nt is 40 nt long; the anchor base A (p1) is mismatched with the endbase C (p40) and forms a small fork; nt p2 to p18 and p23 to p39 form a17-nt stem (S17), and nt p19 to p22 form a small loop of four nt (L4).Furthermore, the Mid domain of Ago2 has a much higher binding affinityfor substrates that have an A or U at the 5′ end, as opposed to a C or G(Frank 2010; Elkayam 2012). Therefore, the 5′ nt should be an A or U. Itwas next reasoned that the CUC 3′ overhang of pre-miR-451 are productsof Drosha/DGCR8 complex and may not be essential for Ago2 processing andsubsequent silencing function because it will be degraded as part of3L12, but that the C at p40 may be used for end base modifications toprevent the RNA from degrading from the 3′ end. Accordingly, thecanonical agsiRNA structure was defined as the 40 nt structureA/U-S17-L4-C (L40, FIG. 1C, 3L12 becomes 3L10 from p31 to p40).

To convert agsiRNA to agshRNA, the choice of promoters and theirtranscription start sites will be critical for their function sinceagshRNA will default 5p as the antisense strand. Several agshRNAs weredesigned that would target the M2 subunit of ribonucleotide reductaseRRM2 gene (R2). The antisense strands were defined as 22 nt long (L22:the first 18 nt plus 4 nt in the loop) and hairpins were expressed bythe U6m promoter (FIG. 6). At least half of the agshRNAs efficientlyreduced R2 protein levels and knocked down expression of a Renillaluciferase reporter gene that had the human R2 cDNA sequences insertedinto its 3′ UTR (FIGS. 7, 8A, 8B 8C and 8D). Thus, the U6m agshRNAexpression vector can express this type of shRNA. To address the concernabout how U6m will start its transcripts if the first nt of L22 is not aG, products from eight R2 agshRNAs were sequenced using small RNA deepsequencing (Sun 2011). In most cases, U6m mainly used bases A and C toinitiate agshRNA transcripts, but the transcription will be initiated atthe upstream C of U6m or the second base in agshRNA if the first base ofthe agshRNA sequence was a T. In addition, Ago2 processed these agshRNAsinto L30, but there are many uridylated and trimmed intermediateproducts were also derived from L30. The length distributions of theseL30-derived intermediates resembled that for isomiR-451 forms that aredocumented in miRBase, suggesting that agshRNA transcripts expressedfrom the U6m promoter are processed by Ago2, similar to the way miR-451is processed (FIG. 9). Accordingly, the canonical agshRNA structure wasdefined as the 40 nt structure, A-S17-L4-C.

The secondary structures of agshRNA and agsiRNA likely differ in howthey form. Presumably, agshRNA is folded in vivo and the single moleculefolded form (SMFF, agsiRNA in FIG. 1C, FIG. 10A) is then exported to thecytoplasm. AgsiRNAs are artificially folded in vitro by denaturing andannealing. Thus, some agsiRNAs will be in the SMFF, while some will bein dimer form. Since the agsiRNAs in the dimer form is not necessary tobe identical, these forms were named cross molecule hybridization form(CMHF). Once the agsiRNAs are transfected into the cytoplasm, Dicershould be able to process the CMHF of agsiRNA into four products (A21,A19, 21C, and 19C in FIGS. 10B and 10C), which will be similar to theproducts generated by RNases that nick the SMFF of agsiRNA between p19and p20 or p21 and p22. Based on this hypothesis, the L40 form ofpre-miR-451 may be less likely to be processed by Dicer than the 42 ntpre-miR-451 form.

AgshRNA-887, -1148, and -1354 was further characterized and theirsynthetic forms, agsiRNA-887, -1148, and -1354, all of which target R2(FIGS. 7, 8A, 8B 8C, 8D and 11) were also characterized. Sli-siRNA-887was used for most of the studies because, among all of the R2 agshRNAsthat were constructed, agshRNA-887 exhibited moderate knockdown of R2(FIGS. 8A and 8B). It was reasoned that it would be easier to observechanges in the potency of this sli-siRNA in response to modifying itsstructure and base composition. The secondary structures of theagshRNA-887 forms used in the experiments are shown in FIG. 12, andindividual structures are listed in FIGS. 13A, 13B, 13C and 13D.

Sli-siRNAs are Ago2-specific and Dicer-independent. The processing ofsli-siRNA-887 and its mutant that had mismatches at central bases (FIG.11, FIGS. 14A and 14B) was tested in Dicer-knockout and Ago2-knockoutmouse embryonic fibroblasts (MEFs). Northern blot analysis and reporterassays showed that both agshRNA-887 and agsiRNA-887 were Ago2-dependentand Dicer-independent, and that Ago2 could not process the mutant formof sli-siRNA-887 (FIG. 11; FIGS. 14A and 14B; FIG. 15). Northern blotanalysis also indicated that the CMHF of sli-siRNA probably exists onlyat very low levels, because the predicted Dicer processed forms (A19)were not detected (FIGS. 14A and 14B). Reporter assays showed thatdepleting Ago2 reduced the silencing efficacy of agsiRNA significantlymore than that of siRNA or rsiRNA, suggesting that agsiRNA mainlyfunctioned through Ago2 RISCs, whereas siRNA or rsiRNA could be loadedinto other Ago RISCs to repress their targets (FIG. 15).

The potency of various concentrations of agsiRNA-887, rsiRNA-887, andsiRNA-887 was also compared. An antisense reporter assay showed thatagsiRNA-887 and siRNA-887 had similar potency, which was higher thanthat of rsiRNA-887 across all concentrations tested. Sense strandreporter assays showed that both siRNA-887 and rsiRNA-887 maintainedstrong sense strand activity (almost as potent as the antisense strand),but agsiRNA-887 had almost three orders of magnitude less sense strandactivity (FIG. 16, FIG. 17). These data suggest that the antisense andsense strands of certain di-siRNAs can be nearly equally loaded intomature RISCs, but RISCs mainly selected the antisense strand forsli-siRNAs.

5′ end modification. Phosphorylation of the 5′ end (5′p) increases thepotency of di-siRNAs (Martinez 2002), and is required for siRNA loading(Schwarz 2003). It has also been proposed that 5′p will hold Ago2 in aspecial conformation (Ma 2005). However, an obvious difference was notobserved in the potency of agsiRNA-887 synthesized with or without the5′p (FIG. 18A). This result agrees with the first bases replacement testin pre-miR-451 (Yang 2012). It is possible that similar to di-siRNA,agsiRNA is phosphorylated in vivo by hClp1 (Ramirez 2008). Accordingly,all agsiRNAs and siRNAs used in the following experiments were syntheticoligonucleotides without 5′p. 5′ end base replacements showed theU-S17-L4-C form performed similarly to the canonical form, but not theC-S17-L4-C form, indicating that an U-S17-L4-C form can be easilyexpressed as an agshRNA that begins with an A (FIG. 18B). It was alsoobserved that extra bases added to the 5′ end affected sli-siRNApotency. The addition of one A, which made the 5′ overhang of theagsiRNA two nt long, slightly increased its potency, but the addition oftwo to four As reduced the potency (FIG. 18C). Northern blot analysisshowed that the amount of mature agsiRNA-887 was reduced when extrabases were added to the 5′ end, implying they are not Ago2 favoritesubstrates and it may be difficult to anchor these molecules to the Middomain of Ago2, or to fit them into the Ago2 substrate groove to triggerAgo2 slicer activity. The lengths of the long fragments and matureproducts were also increased, suggesting that the Ago2 slicing sites on3p were not shifted by adding extra bases to the 5′ end and supporting amodel that Ago2 slicing sites are defined by the stem region of agsiRNA(FIG. 19A).

3′ end overhangs. The original pre-miR-451 has a 3′ overhang of CUC thatarises from Drosha processing. When the agsiRNAs were designed, it wasassumed that the last two bases would not be required foragsiRNA-mediated gene silencing. Firstly, because they would be degradedas part of the 3L12 after Ago2 nicks the substrate, and secondly,because experiments with the R2 agshRNAs showed that the UC bases couldbe replaced by UU. However, these bases could maintain the structure ofthe substrate to allow efficient Ago2 binding and processing, or protectpre-m iR-451 from being degraded from the 3′ end. To test the functionof different overhangs at the 3′ end of agsiRNA, these bases werereplaced with modified bases that were resistant to RNases to preventagsiRNA degradation from the 3′ end. 3′ end variants of agsiRNA-887 werecreated by attaching U, UU, or UUUUU, or deoxy T deoxy T (dTdT) to thelast C, or by converting the last C to a dideoxy C (ddC). Northern blotanalysis showed that the UUUUU form produced fewer mature products,indicating increased degradation of this agsiRNA. Both the U and UUmutants produced slightly less product than the canonical form, and thedTdT and ddC forms produced mature products in similar amount towild-type (“wt” in FIGS. 19A and 19B). Reporter assays showed that themodified 3′ end bases, which were removed together with the shortfragments, had little effect on the silencing potency of the matureagsiRNAs (FIGS. 18D and 18E). Because the ddC modification can preventdegradation from the 3′ end, it would be a good addition to the designof agsiRNAs to increase their stability in vivo.

Base pairs in the stem Region. The stem region can be divided into theseed, central, and 3′ supplementary (3′ supp) regions (FIGS. 1A, 1B and1C). Because the central bases are critical for the slicing reaction,only mismatches, GU wobbles, and bulges were introduced into the seedand 3′ supp regions to determine their effects on sli-siRNA processingand silencing potency. In contrast to the reported miR-451 processingdata that G:G mismatch for p6:35 enhances miR-451 function (Yang 2012),the Northern blot analysis showed that agsiRNA-887 with mmp6 (base #6mismatched with #35) and mmp7 modifications produced fewer matureproducts than wild-type agsiRNA-887, and the effects on agshRNA wereeven stronger (FIGS. 19B and 19C). AgshRNA-887-mmp8, -mmp13, -mmp14,-mmp15, -GU-p8, and -bulge-p7 were also processed poorly; the amounts ofmature products were dramatically reduced (FIG. 19C). WhileagshRNA-887-mmp13, 14, and 15 data agreed with the published miR-451mutation data, agshRNA-887-mmp8, -GU-p8, and buldge-p7 showed a muchstronger effect on the silencing potency and processing efficiency ofsli-siRNA-887 than miR-451 mutations at these positions (Yang 2012).These data indicate that base pair modifications in the stem regionaffect agshRNA more severely than agsiRNA and also suggest that the seedregion has more flexibility for mismatches and wobble base pairs, butbulges are not favored. It is possible that a mismatch (flexible for ntat any position) or a wobble base pair (context dependent, only for ‘G’or ‘U’) in the seed bases could help release the 3L10 from the L30, andfacilitate the binding of products trimmed from L30 to their targets(Yang 2012). Despite having the similar knockdown potency at higherconcentrations, there was a several fold drop in the activity of themmp6 and mmp7 mutants at lower concentrations compared to wild-type(FIG. 18G). The published result that mismatch of p6:35 (G:G) enhancesmiR-451 potency was also revisited (Yang 2012). The reporter assaysusing three natural existing miR-451 forms, the human (hmiR-451, G:Uwobble pair for p6:p35), mouse (mmiR-451, G:C pair for p6:p35), andzebra fish miR-451 (dmiR-451, G:G mismatch pair for p6:p35), revealedthat hmiR-451 was the most potent and dmiR-451 was the least potent inboth target cleavage and repression (FIG. 4A; FIGS. 20A and 20B). It wasalso observed that the three forms of pre-miR-451 exist almost equallyin nature. There are six G:G, six G:C, and five G:U paired pre-miR-451sin 18 species that were documented in miRBase 19 (FIG. 4A). Therefore,both our sli-siRNA-887 and pre-miR-45 results argue against theconclusion that the flexible base pairing of p6 with p35 in pre-miR-451senhanced their potency. But, they support the hypothesis that theflexible base pairing of p6 with p35 in pre-miR-451s may arise fromnatural selection in balancing short fragment release and mature 5pbinding to targets (Yang 2012). The p6 G of miR-451 may act as a ‘pivot’residue for target recognition like the p6 C of miR-124 (Chi 2012).

Optimal stem length. When one more mismatch by was added to the 5′/3′ends of the sli-siRNA hairpin (mmp2, 16 nt stem), the structure behavedlike the canonical form. But, if two more bps (mmp2-3, 15 nt stem) wereopened, the production and function of the mature form were negativelyaffected (FIGS. 18F and 19B). When the stem was opened from the loopregion, which increased the loop size to 6 nt (mmp18, 16 nt stem), 8 nt(mmp17-18, 15 nt stem), or 10 nt (mmp16-17-18, 14 nt stem), only themmp18 behaved like the canonical form (FIG. 19B; FIG. 18F). Next, anextra nt at the end of the agshRNA-887 stem (p18) was removed or added,but only the S18 (18 nt stem) was processed like the S17. Both the S19and S20 forms were processed into less mature products, and theprocessing generated multiple products or intermediates (FIG. 19D). Thisagrees with the published results that Dicer and Ago2 will compete forprocessing shRNAs with stems of this range (Gu 2012; Liu 2013). For theshort stem variants, only S16 was processed like the canonical S17; therest produced less mature product for both agshRNA and agsiRNA, andthese data correlated well with the reporter assay results (FIGS.19D-19F). Northern blot data for both agshRNA-887 and agsiRNA-887 showedthat the most noticeable processing defect that mature products weremostly lost when the stem was shortened from 15 to 14 bases (FIGS. 19Dand 19E). Therefore, it is likely that Ago2 cannot efficiently processsubstrates with stems shorter than 15 bases. Similar results werereported in sshRNA study and agsiRNA study (Ge 2010; Ma 2014). Thisresult supports the conclusion that the optimal length of the stem ordsRNA needed to fit into the Ago2 groove and trigger the Ago2 sliceractivity is ˜16 bases and agrees well with the length of the dsRNAregion in the molecules of several potent siRNA variants reported (Sun2008; Chang 2009; Chu 2008).

The small loop makes a difference. To test whether the four nt loop isrequired for silencing, the 5′ and 3′ ends were paired, p19 was pairedwith p22, and p20-p21 was replaced with UU to convert the agsiRNA-887into sshRNA-887 (Ge 2010). Next, a no-loop version (NL) of bothagshRNA-887 and agsiRNA-887 was made by directly connecting the first 19nt of sli-siRNA-887 with its complementary strand. The major matureproducts from sshRNA-887 were less and shorter than agsiRNA-887 andthere were many products longer or shorter than the major band on theblot (FIG. 19B). If RRM2 agshRNA-1111 is considered as a special case ofsshRNA because its p20-21 bases are UU, the deep sequencing data showedthis agshRNA produced almost equal amount of 5p and 3p products with aclear cleavage by unknown RNases between the UU (FIG. 9), and both 5pand 3p reads from this agshRNA actually are low compared to other 7agshRNAs being sequenced. The processing of NL was affected, and thesilencing activity of the NL form was several folds lower than that ofthe wild-type (FIG. 16). There were much less mature products for boththe agsiRNA and agshRNA versions of NL (FIGS. 19B, 19C, and 19E).

Whether the sequence context of the loop affected its potency was testedby changing the bases from p18 to p23 (tail bases) in agsiRNA. Theeffects on gene silencing were also tested. The tail bases ofagsiRNA-887, -1148, and -1354 were replaced with the tail bases frommiR-451 (GAGUUU: LP451), which caused a five-fold reduction in potencyfor agsiRNA-887, whereas the potency of agsiRNA-1148 increased, and thepotency of agsiRNA-1354 showed no difference (FIGS. 21A, 21C, and 21D).The tail bases of agsiRNA-1148, agsiRNA-1354, and hmiR-451 were thenreplaced with the tail bases of agsiRNA-887 (GGAUGU: LP887). This changeled to a slight increase in potency of agsiRNA-1148, whereas the potencyof agsiRNA-1354 was not changed, and the potency of hmiR-451 was reducedabout five-fold (FIGS. 21B, 21C and 21D). These data indicate the loopsequence (p18 to p23) may influence the silencing potency of sli-siRNA(FIGS. 21A, 21B, 21C and 21D). Therefore, the native sequence of thetarget should be used for the loop.

Activity of the L30. It has been shown the L30 of miR-451 is inactive(Yang 2012). To test the activity of L30 of agsiRNA-887, nts wereremoved from the 3′ end to generate L39 (39 nt, wt is L40), L38, L37,L35, L30, L29, L27, and L25 forms of agsiRNA-887. Both L39 and L38behaved like L40. However, the amount of mature processed products fromL37 and L35 was dramatically reduced, as was their gene silencingactivity in reporter assays (FIGS. 19G and 19H). No mature products wereobserved that were processed from L30 or the other shorter forms;instead, unprocessed CMHFs of these molecules were detected on Northernblots (FIG. 19G). More importantly, when L30 annealed with 3L12, itmimicked the intermediate products that were sliced from an agsiRNA byAgo2, and showed a ˜2-fold increase in activity over L30, which washundreds of fold lower than the activity of L40 (FIG. 16). These dataindicate that, unlike di-siRNA, which can use a segmented passengerstrand (Bramsen 2007), sli-siRNA need the intact hairpin to be potent(Yang 2012).

Target cleavage and repression by sli-siRNAs and di-siRNAs. Next,silencing potency was compared, including both target cleavage andrepression activities, by the two types of RNAi triggers using reporterassays.

For the target cleavage activity, a reporter was co-transfected thatcarried one copy of the perfectly matched target sequence of miR-451with hmiR-451, mmiR-451, dmiR-451, or siRNA-451 (si-451: di-siRNAcontaining L21 of the miR-451 sequence). Time course experiments showedthat si-451 silenced the reporter in significantly less time than allthe miR-451 genes. Knockdown by si-451 peaked at approximately 24 hpost-transfection, whereas knockdown by miR-451 peaked at approximately36 h post-transfection. However, similar silencing levels were obtainedusing hmiR-451 and si-451 36 h post-transfection (FIG. 20A). Theseresults may indicate that the Ago2 processing step or maturation stepslowed down the onset action of sli-siRNA because there are manyprocessing intermediates one day after transfection on Northern blots(FIG. 22).

For target repression activity, four reporters were created with miR-451seed or sequences that base paired with the 3′ supp region, or both aspartially complementary targets. Each reporter had four copies of thetarget sequences in tandem in order to see the cooperative bindingeffect of multiple RISCs (FIG. 20C). It was found that althoughmismatches in the seed were somewhat tolerated in gene silencingmediated by target cleavage, they were not well tolerated by eithersli-RISC or di-RISC for translational repression. However, mismatches inthe sequences that base paired with the 3′supp region were welltolerated by both sli-RISC and di-RISC. There was no significantdifference between the silencing effect on targets that had only theseed, or the seed plus sequences that base paired with the 3′suppregion. There was a significantly higher repression activity for allthree reporters that carried the intact seed by si-451 compared to thethree miR-451 species. This difference could be due to the ability ofnon-slicing Agos to participate in si-451-mediated repression, but notin miR-451-mediated repression, which functions solely through Ago2(FIGS. 20A and 20B).

In vivo expression and potential applications of sli-siRNAs. First, theability of sli-siRNAs to activate the innate immune response wasexamined. Results indicated that the ability of sli-siRNAs to activatethe innate immune response was very low, which agrees with the reportedresults from sshRNA study (FIG. 23) (Ge 2010). Next, the designparameters were put into practice to generate sli-siRNAs that wouldtarget other endogenous genes. The R2 partners R1 and R2B were knockeddown by using sli-siRNAs (FIGS. 24A, 24B, 24C and 24D). However, themajor concern regarding their usage, especially in vivo, is whethersli-siRNAs would saturate the endogenous miRNA pathways because theyrequire Ago2 for processing and function. This concern is due to thetoxicity of traditional shRNAs in that some of them could jeopardize thenuclear export of endogenous miRNAs by Exportin-5 and compete withendogenous miRNAs for Ago proteins (Grimm 2010). Stable, constitutive orinducible agshRNA expression systems were built using lentiviruses (FIG.6). Sli-sRNA-1148 was chosen for these experiments because it has a 6 ntloop (mmp18) and two GC pair sites that can be converted into two GUwobble sites to better resemble the canonical pre-miRNA structure tocompete with endogenous pre-miRNAs (FIGS. 7 and 8A, 8B, 8C and 8D).

First, these lentiviral constructs were transiently transfected intoHEK-293 cells to evaluate their expression and processing. Wt, mmp7, andGU transcribed from U6m, and wt transcribed from U6TO, (a Doxycycline[Dox]-inducible U6m), were strongly expressed and easily detected onNorthern blots. Wt and mmp7 had the most mature species, and the GU formhad more unprocessed products, probably because of the double G:U bpsintroduced into the structure. There was no observable differencebetween mature miR-21 levels in the transfected cells (FIG. 25A). Next,lentiviral vectors were constructed that contain restriction sitesengineered for cloning U6 driven agshRNA expression cassettes (vector).AgshRNA was constructed with scrambled sequences as the negative control(ctrl), agshRNA-1148-mutant (mut; nt at p10-12 were swapped with theirbase pair partners on 3p; it can still be processed by Ago2), -1148wild-type (wt), -1148-mmp7 (mmp7), and -1148-Gup27p36 (GU; Cs at p27 andp36 both replaced with Us to create wobble bps at these positions) intothe lentiviral vectors (FIGS. 7 and 8A, 8B, 8C and 8D).

Cell lines were made that stably express wt, mmp7, GU, or mut ofagshRNA-1148. Both R2 protein and mRNA were reduced in the cell linesexpressing wt, mmp7, or GU (FIGS. 26A and 26B). Northern blot analysisrevealed that processed products were present in these cell lines, andthere were no observable changes in the levels of either thepre-miRNA-21, or mature miRNAs of miR-21 and miR-31 (FIG. 26C; FIG.25A). The levels of miR-21 (high expression), miR-31 (mediumexpression), and miR-143 (low expression) were measured in the stablecell lines by miRNA qPCR. There were no significant changes in miR-21 ormiR-31 levels across all samples. There was some variation in miR-143levels in the mmp7 and GU samples, but this may be due to technicalvariations that can occur when using qPCR to quantify miRNAs that havevery low expression levels (FIG. 25B). The inducible expression of wtand mut agshRNA driven by the Dox inducible U6TO promoter was alsoevaluated. After adding Dox, products processed from the wt and mutagshRNA-1148 were detected on Northern blots, and R2 levels were reducedin the cells expressing wt agshRNA-1148. Very low amounts of processedproduct could be detected in wt samples that were not treated with Dox,indicating that the U6TO promoter was slightly leaky. The leakage shouldnot be a concern because it will not produce enough amount of matureagshRNA for effective target knockdown (FIG. 26D).

The proliferation rates, invasiveness and wound healing abilities of theabove stable cell lines were compared. Real-time cell proliferationexperiments showed that wt and mmp7 grew much more slowly than the othervariants (FIG. 25C). Matrigel invasion assay showed that cellsexpressing wt, mmp7, or GU were less invasive than other variants (FIG.25D). In addition, wound healing assays showed that cells expressing wt,mmp7, or GU did not close the wound gaps as quickly as the othervariants (FIG. S25E). Non-transduced cells, cells transduced with vectoronly, or ctrl RNA had similar proliferation rates, indicating thatscrambled agshRNA did not titrate Ago2 protein away to affect cellgrowth. Therefore, agshRNA have potential for in vivo applications totarget genes involved in the pathogenesis of human diseases, such ascancer.

Discussion

As shown in the example herein, the structural parameters were definedfor designing and expressing sli-siRNAs that are as potent as classicaldi-siRNAs, but have much less sense strand activity, and their potentialfor physiological use in mammalian cells was demonstrated. Sli-siRNAscan be effectively expressed by a modified U6 promoter to mount a potenttarget knockdown, but not H1 or U1 promoter with similar modification,presumably due to much weaker transcription by H1 or U1 promoter uponmodification (FIG. 19D; FIG. 25A; FIGS. 27A, 27B and 27C). Sli-siRNAshave not only fewer off-target effects by the sense strand, but they arealso are easier to design than di-siRNAs because they have 5p as theantisense strand as default and can avoid the concern of endthermodynamics stability in di-siRNA design (Khvorova 2003). Because ofsimilar function mode and molecular structure between sshRNAs andagsiRNAs, the effect of chemical modification on sshRNA should also beapplicable to agsiRNA (Ge 2010). The biogenesis mechanism of sli-siRNAsalso assumes that incorporation of the sli-siRNAs into non-slicing AgoRISCs will be limited and will avoid the competition for Dicer withendogenous miRNAs (Dueck 2012; Yang 2012; Ma 2014). Therefore, it ispossible that sli-siRNAs may also reduce the RNAi off-target effectsthat are caused by strands being loaded onto non-slicing Agos (Petri2011). Nevertheless, agsiRNAs clearly have advantages over di-siRNAs,including being single stranded and self-destroying passenger strandduring maturation, as well as needing only one synthetic setupprocedure, one purification procedure, and fewer nt modifications.Therefore, sli-siRNAs are a viable option for developing novel, potentRNAi triggers.

Although sli-siRNAs and di-siRNAs have similar potency in both targetcleavage and repression, there are some differences in their functionalmechanisms and may deserve further studies. First, di-siRNAs can use anyof the Agos, whereas sli-siRNAs only use Ago2. Second, there is anuridylation and 3′ trimming step during sli-siRNA maturation, and it isexpected that the rate for this step will be sequence-dependent, e.g.,uridylating at U is not necessary and the trimming rate for different ntis not known. It has been shown GC rich sequences in the trimming regionwill result in poor potency (Yang 2012). The maturation step may causesli-siRNAs to have a slower silencing rate at the onset. Third,di-siRNAs need go through strand selection, passenger stranddisplacement, and conformational change for guide strand loaded di-RISCto activate RISCs, whereas sli-siRNAs activates RISCs during itsmaturation step. The sli-siRNA maturation step may also be able tocouple with its silencing function.

In summary, because the sli-siRNA molecule itself enables superbantisense strand selection, it is strongly believed that sli-siRNA willbe a viable option as potent RNAi triggers.

Materials and Methods

Antisense sequence selection. The sequences for the L22 forms ofsli-siRNAs that targeted the M2 subunit of ribonucleotide reductase(RRM2, or R2) were selected using SiRNA Site Selector (siDuplex), whichcalculates the theoretical difference in thermodynamic stability of theends of an siRNA duplex, and the relative accessibility of the targetsites for optimal siRNA design(http://infosci.coh.org/HPCDispatcher/Default.aspx) (Neale 2005). Thelength of the duplex region was changed to 20 nt and two nt from thenative sequence were used as the 3′ overhang. The sequences for the L22forms of the sli-siRNAs that targeted R1 and R2B were selected using theSi-ShRNA Selector set at the default settings, except the length of theduplex was changed to 20 nts. Si-ShRNA Selector uses a differentalgorithm from siDuplex for selection of antisense strands. It wasdesigned to use the same antisense sequence for both the siRNA andshRNAs, and takes GU pairs and accessibility into consideration(Matveeva 2010).

Cell lines and cell culture. HEK-293 cells, HCT-116 cells, Ago2-knockoutMEFs, and Dicer-knockout MEFs were maintained in high glucose (4.5 g/1)DMEM supplemented with 2 mM glutamine, 10% FBS, and 2 mMpenicillin/streptomycin. Cells were incubated at 37° C., 5% CO2.

Transfection. For reporter assays, shRNA expression plasmids andreporter constructs were co-transfected into cells by usingLipofectamine 2000 (Invitrogen). For each experiment, at least threeindependent transfections were performed in duplicate in 24-well plates.Cells were grown to 75 to 85% confluency in 500 μl medium, and weretransfected with reporter (50 ng), agshRNA, or differing amount of siRNAor agsiRNA (100 ng of U6-agshRNA vector as stuffer DNA, plus 1 μl of 5μM, 1 μM, 200 nM, 40 nM, 8 nM, 1.6 nM, or 0.32 nM siRNA or agsiRNA, and1 μl of Lipofectamine 2000).

For RNA isolation and immunoblots, plasmids (4 μg) or 5 μl of 5 μM siRNAor agsiRNA were transfected into cells in six-well plates, using 10 μlof Lipofectamine 2000 or 5 μl RNAiMAX per well. Prior to transfection,cells were grown to 75 to 85% confluency in 2 ml of culture medium.

Dual-luciferase reporter assays. All reporter assays were performedusing psiCheck 2.0-based, dual-luciferase reporters from Promega thatexpress both firefly luciferase (Fluc) and Renilla luciferase (Rluc).Reporters carried complementary target sequences that were constructedby inserting annealed oligonucleotides or digested PCR products into theXho I/Spe I sites of the 3′ UTR of the Rluc gene in psiCheck2.2 vector(Sun 2009). These reporters were used to quantify gene silencing. Fortyeight hours after transfection, cells were lysed with 100 μl passivelysis buffer (Promega) and luciferase levels for 20 μl of lysate weredetermined (Dual-Luciferase reporter assay kit, Promega; VeritasMicroplate Luminometer, Turner Biosystems). Changes in expression ofRluc (target) were calculated relative to Fluc (internal control) andnormalized to the agshRNA expression vector (U6-agshRNA) or scrambleagsiRNA control. The normalized relative ratios of Rluc/Fluc were usedto measure the efficiency of silencing. Data were averaged from leastthree independent transfections and each transfection had at least tworeplicates. Error bars indicate the standard deviation.

AgshRNA expression vectors. Design of both the constitutive (U6-agshRNA)and inducible (U6TO-agshRNA) expression vectors for agshRNAs was basedon a previously reported shRNA expression vector that contains the U6promoter (Aagaard 2007). Constitutive expression was achieved bytransducing cells with lentiviral vectors that expressed U6-agshRNAcassettes (FIGS. 6, 28 and 29A and 29B). To create inducible vectors,part of the 3′ end of the U6 promoter sequence was mutated into a TetRbinding sequence (U6TO) as previously described (Aagaard 2007) (FIGS. 6,28, and 29A and 29B). All shRNAs were cloned by ligating annealedoligonucleotides into Bgl II and Xho sites.

Lentiviral vector construction. The lentiviral vector pHIV7-EGFP (Li2003) was modified by replacing the EGFP expression cassette driven bythe CMV promoter with a puromycin (Puro) expression cassette driven bythe SSFV promoter to generate SSFVLV-Puro. The lentiviral vectorpHIV7-TIG (Tet repressor-IRES-eGFP) (Aagaard 2007) was modified byreplacing the EGFP gene cassette with the Puro gene cassette to generatethe CMVLV-TIP (Tet repressor-IRES-Puromycin) vector (FIG. 6). U6-agshRNAwas cloned into SSFVLV-Puro for stable, constitutive agshRNA expression,and U6TO-agshRNA was cloned into CMVLV-TIP for stable integration andinducible agshRNA expression.

Lentiviruses production. Lentiviruses were produced as described (Li2008). Lentiviruses were used to infect HCT-116 cells, and positiveclones were screened in media containing 1 ng/ml Puro. Expression ofmature processed products was analyzed by northern blot.

RNA isolation and northern blot analysis. RNA isolation, northern blotanalysis, and small RNA cloning were carried out as described (Sun2009). Briefly, RNA was extracted using Trizol, total RNA (20 μg) wasseparated on 12% SDS-PAGE/8% urea gels, and gels were blotted ontopositive charged nylon membranes. A DNA oligonucleotide probecomplementary to the target RNA sequence was labeled with γ-32P-ATP. Theprobe was hybridized to the membranes overnight in PerfectHyb Plushybridization buffer (Sigma), after which membranes were washed once in6×SSPE/0.1% SDS for 10-30 min and twice in 6×SSC/0.1° A SDS for 10-30min each. U2 or U6 snoRNAs were used as RNA loading controls.

Small RNA deep sequencing. Deep sequencing of small RNAs derived fromagshRNA was performed using the HiSeq-2000 platform (Illumina). SmallRNA library construction and sequence read analyses were conducted asdescribed24. Briefly, 1.0 μg of total RNA was used to construct smallRNA libraries for single reads, flow cell cluster generation and 42cycle (42-nt) sequencing.

Real-time cell proliferation assay. ACEA Biosciences RT-CES was used tomonitor cell growth in real time. This system uses microelectronic cellsensor arrays that are integrated at the bottom of microtiter plates tomonitor cell growth by measuring changes in electrode resistance.Measurements were taken every 30 min during the 3 day incubation.

Wound healing assay. Cells were grown in 24-well plates to at least 90%confluency, scratched using pipette tips, washed with PBS, and thencultured in complete medium for about two days to allow cells to migrateinto the wound areas or until the scratched areas in control cells werefilled. Wound areas were photographed before and after the 2 dayincubation.

Cell invasion assay. Cell invasion assays were performed with cellinvasion chambers (BD Biosciences), according to the manufacturer'sinstructions. Infiltrated cells were stained with Diff-Quik Stain Kit(Fisher Scientific) 24 or 48 h after plating. Three random areas werechosen for analysis; cells that had infiltrated these areas were countedand averaged.

Bioinformatics analysis. RNA and DNA secondary structures were predictedby mFold (Zuker 2003), the Vienna RNA software package (Hofacker 2003),and RNAstructure (Reuter 2010). CLUSTALW and Jalview (Waterhouse 2009)were used to perform multiple sequence alignments. Three dimensional RNAstructures were predicted using the MC-FoldIMC-Sym pipeline (Parisien2008) and RNAcomposer (Popenda 2012). 3D structures were viewed usingPyMOL (The PyMOL Molecular Graphics System, Version 1.5.0.4 Schrödinger,LLC).

Oligonucleotides. All oligonucleotides were synthesized by IntegratedDNA Technologies; sequences are listed in FIG. 28.

Immunoblotting. R2, R1, R2B, GAPDH, and beta actin antibodies werepurchased from Santa Cruz Biotechnology Inc. Western blot analyses wereperformed as previously described (Sun 2010). Briefly, cells in six-wellplates were washed with cold PBS (2 ml) and lysed in 0.3 ml M-PERmammalian protein extraction reagent (Pierce). Samples were centrifugedat top speed for 10 min, then supernatants were collected. A proteaseinhibitor cocktail (Roche) was added to the supernatants, and theprotein concentration of each sample was quantified by Bradford assay(Bio-Rad, protein assay dye). Twenty micrograms of total protein fromeach sample was separated by SDS-PAGE at 100 V for 2-3 h, and thenelectro-blotted at 15 V onto Hybond-P PVDF membranes (GE Healthcare) for30 min. The membranes were blocked in TBS-T (0.05% Tween 20) plus 5%milk for at least 1 h at 4° C., and then probed with primary antibodiesovernight at 4° C. After washing, the membranes were probed withsecondary antibodies for 1 h at 4° C. and visualized using standard APdetection chemistry (ECL western blotting substrate, Pierce).

Example 2 Differences in Silencing Highly Complementary Targets bySliced Versus Diced RISCs

The biogenesis of most miRNAs involves the enzyme Dicer, which processesthe precursor-miRNA (pre-miRNA) hairpin in the cytoplasm to create 21 to23-nt duplex RNAs (5p/3p) with a 3′ end overhang. Dicer also chopsdouble stranded RNAs (dsRNAs) into canonical siRNAs (di-siRNAs) asduplexes of guide strand/passenger strand that have a 19 base pair dsRNAstem with an overhang of two nt at the 3′ end of each strand (FIG. 30A)(Foulkes et al. 2014). Next, these small RNAs (smRNAs) are loaded ontoAgos to form RNA induced silencing complex (RISC) to cleave fullycomplementary targets or repress partially complementary targets (Ha andKim 2014). Interestingly, miR-451 and a few other miRNAs use an elegantslicing biogenesis mechanism that involves Ago2, but not necessarilyDicer (Cheloufi et al. 2010; Cifuentes et al. 2010; Yang et al. 2010;Sun et al. 2015). This mechanism was used to design sli-siRNAs that aremainly processed by Ago2 and have significantly reduced sense strandactivity (FIG. 30B) (Ge et al. 2010; Dueck et al. 2012; Yang et al.2012; Liu et al. 2013; Ma et al. 2014; Sun et al. 2015). Despite thefact that sli-smRNAs solely function through Ago2 while di-smRNAs canfunction through all Agos, both types of RNAi triggers show similarpotency in target cleavage and repression (Yang et al. 2012; Sun et al.2015).

As provided herein in Example 2, it was found that sli-smRNAs are morepotent than di-smRNAs for highly complementary targets and thisdifference is more apparent in targets with mismatched nucleotides thatare located in the 3′ supplementary base pair region compared to thoselocated in the seed region. This phenomenon may be explained byengagement of both slicing and non-slicing RISCs in di-smRNAs(di-RISC)-mediated silencing, whereas only slicing RISC is used insli-smRNA (sli-RISC)-mediated silencing, which may result in differentdynamics of di-RISC compared to sli-RISC. This observation can befurther explained by the different functional mechanisms in slicing RISCactivation: Activated di-RISCs are loaded with 21-mer guide RNAs, butsli-RISCs mainly use 23-26 mers as guide RNA. Therefore, based on thelength and tertiary structure of smRNAs in activated RISCs, it isproposed herein that sli-smRNAs fit into the fixed-end model, whereasdi-smRNAs fit into the two-state putative Ago functional model. Theresults provided herein suggest that a guide strand from sli-smRNA willcause substantially stronger off-target effects than the same guidestrand from di-smRNA and that the duplex RNA generation step by Dicerplays a pivotal role in the specificity of RNAi targeting.

Results

Despite reports of sli-siRNA being as potent as classical di-siRNA forboth target cleavage (fully complementary targets) and target repression(partially complementary targets) (Yang et al. 2012; Ma et al. 2014; Sunet al. 2015), it was thought that these two types of RNAi moleculesmight have different targeting dynamics during silencing becausedifferent Ago-mediated RISCs will be involved, and sli-siRNAs also needto be uridylated and trimmed at bases p30 to p23 during maturation (FIG.30B) (Cheloufi et al. 2010; Cifuentes et al. 2010; Yang et al. 2010;Yoda et al. 2013). It was hypothesized that highly complementary targetswill put RISC into mixed action mode of cleavage (fast) and repression(slow), and the tolerance of mismatches in targets may revealdifferences in silencing between these two types of RNAi triggers.Mutations were introduced in targets to create reporters carryingmismatches between the target and the RNAi molecules: two mutations werecreated for each position and mutations at one position are differentfrom another by two bases. Wild type (wt: fully complementary) andmutants (mut: one or two nucleotides (“nts”) mismatch) reporters forpreviously categorized sli-siRNA-887 that target RRM2 (Sun et al. 2015),sli-siRNA-ARX1 that target ARX gene, and mouse version pre-miR-451(mmiR-451) converted sli-siRNA-451 were created for this experiment(FIG. 31).

Sli-smRNAs have much stronger tolerance for mutated targets, especiallymutations at the 3′ supplementary regions of targets. In smRNAtargeting, the sequence of smRNA or its base pair region on a target canbe divided into three regions: the seed, central, and 3′ supplementary(3supp) regions (FIGS. 30A-30C) (Wee et al. 2012). Many lines ofevidence have shown that siRNAs/miRNAs use the ‘seed’ to nucleate theirbinding to targets and the 3supp region stabilizes RISC for action(Lewis et al. 2003; Brennecke et al. 2005; Lewis et al. 2005; Wee et al.2012; Schirle et al. 2014).

The dosage of sli-887 or di-887 that can knockdown the fullycomplementary reporter by about 95% was first optimized, then thesli-887 and di-887 knockdown efficiency for a set of highlycomplementary reporters under the same condition was compared (FIG. 32).Despite the expected context-dependent influences of some mutatedsequences, sli-887 tolerated mismatches in the target much better thandi-887 (FIG. 33). The difference was more obvious for targets withmutations in the 3supp region (FIG. 34). For some mismatched reporters,sli-887 even had a several-fold higher knockdown efficiency than di-887(FIG. 33). Next, the C at position 14 (p14C) in sli-887 was mutated to aG or U, creating the mutant sli-887-C14U and -C14G (their perfectlymatched 5p targets will be mismatch reporters G14A and G14C ofsli-887-5p, respectively, FIG. 32). Sli-887-wt, -C14U, and -C14G, andthe corresponding di-887-wt, -C14U, and -C14G, had similar silencingpotencies for perfectly matched targets, but sli-siRNAs were more potentfor mismatched targets than di-siRNAs (FIG. 35). Sli-887 was also morepotent than di-887 for silencing reporters that carried two mismatches(U6G-U12G and U4C-U15C; FIG. 35). The two G:U wobble pair reporters(A10G and A16G) showed similar knockdown effect, which is also anindication that sli-siRNAs have higher tolerances for mismatch targets(FIG. 33).

The above observations were further tested using a set of reporters forsli-siRNA-ARX1 (sli-ARX1) (FIG. 36). This time the dosage of sli-siRNAor di-siRNA was titrated to knockdown the fully complementary reporterby about 80%. The data clearly showed that sli-ARX1 tolerated mismatchesin the target much better than di-siRNA-ARX1 (di-ARX1), and the formeris much more potent than the latter when the mismatches are located inthe 3supp region versus in the seed region. When the mismatches arelocated in the seed region, the sli-siRNA and di-siRNA have similarknockdown efficiency, whereas the knockdown rate by sli-ARX1 is abouttwo-fold of that by di-ARX1 for most mismatch reporters with mismatcheslocated in the 3supp region (FIG. 37).

The above siRNAs that target RRM2 and ARX are artificially designedsequences that showed similar knockdown effect but also exhibitedsequence context dependent differences in silencing (FIGS. 33, 37).Whether the miR-451 sequence which has been selected during evolutionshows similar properties remains unknown. We performed a similar assayfor miR-451 using highly complementary reporters (FIG. 38). Our resultsshowed that the ability of the mmiR-451 converted sli-siRNA-451(sli-451) to tolerate mismatches was significantly higher than that ofsiRNA mimics of mature miR-451 (di-451), and the differences were moresignificant for targets that had mismatches in the 3supp of targets.These results also indicate that the miR-451 sequence exhibited thedifference across all target regions (FIGS. 39, 40).

Sli-RISC uses 23 to 26-mer smRNAs for function. Published Northern blotdata and in vitro processing data of pre-miR-451 mimics indicated thatthe sli-siRNA mainly present as 23 to 26 nt processed products (Yang etal. 2012; Yoda et al. 2013; Sun et al. 2015). While poly(A)-specificribonuclease was identified as the enzyme responsible for 3′-5′ trimmingof Ago2 resected pre-miR-451 mimics, the trimming step per se isdispensable for miR-451 mimics silencing function in vivo, supportingthe idea that sli-RISCs can use longer intermediate guide RNAs fortarget silencing (Yoda et al. 2013). Deep sequence reads of both humanand mouse miR-451 isoforms documented in miRBase were analyzed. It wasfound that the L23 to L26 forms cover almost 70% of isomiR-451 (FIGS.41A, 41B). Therefore, it is possible that sli-RISC and di-RISC usedifferent length of guide smRNAs and the tertiary structure of thesefunctional smRNAs may lead them to adapt a different mechanism offunction.

The hairpin structure of sli-smRNA and the duplex structure of di-smRNAmay initiate RISC differently (FIG. 42A). Studies on the properties ofsli-siRNA also support this hypothesis. In contrast to the tolerance ofmutation in the 3supp of a target, mismatches in the 3supp of sli-smRNAmolecules exhibited a much stronger effect on both sli-smRNA processingand silencing potency than mismatches in the seed region (Sun et al.2015). It appears that base pairs at the 3supp of a sli-smRNA areimportant to maintain sli-RISC in a catalytically competentconformation, but base pairs at 3supp between sli-smRNA and targets areless important for silencing effects. This result suggests that thegroove formed by the PIWI, PAZ, N domains, and L1 linker in Ago2 (PPNL1groove, FIG. 42B), where the 3supp region of sli-siRNAs resides, isimportant for positioning Ago2 into its catalytically competentconformations. These observations are consistent with the finding thatthe domains at the N terminus (N-L1-PAZ) of Ago2 are critical forcorrectly aligning the target RNA with the Ago2 catalytic center forslicing (Faehnle et al. 2013; Hauptmann et al. 2013; Hauptmann et al.2014). The groove formed by the PAZ, PIWI, Mid domains, and L2 linker(PPML2 groove, FIG. 42B), where the seed region resides, has moreflexibility for mismatches and wobble base pairs. This may facilitatethe subsequent release of short fragments and mediate target binding,but the PPNL1 groove will be important for maintaining sli-RISC in thecatalytically competent conformation.

Discussion

The discovery of miR-451 biogenesis and functional mechanism has raisedan intriguing question: why did nature not select Ago2 as the sole RNAifactor and eliminate Dicer and non-slicing Agos during evolution?Instead, most miRNAs use Dicer generated intermediates that can beloaded onto all Agos for function. Only a few miRNAs use the seeminglysimpler Ago2 processed pathway (Cheloufi et al. 2010; Cifuentes et al.2010; Yang et al. 2010), despite smRNAs generated from both pathwayshaving similar silencing potencies toward target cleavage and repression(Yang et al. 2012; Ma et al. 2014; Sun et al. 2015). The results fromthe experiments in Example 2 herein showed that sli-RISC and di-RISCexhibit different potency in silencing highly complementary targets.

One simple explanation for this observation is that displaced passengerstrand or cleaved passenger strand fragments could act as target decoysand compete with targets for activated RISCs. Sli-RISCs will generate a10-nt short resected passenger strand and di-RISCs can generate twoshort (10 nt and 11 nt) passenger strand fragments through passengerstrand cleavage and a full length passenger strand through passengerejection. In the case of di-RISC, the full length passenger strand couldcompete much better with mismatched target for active RISC thanfragments of passenger strands, and the cleaved passenger strandfragments from di-RISCs can bind to both seed and 3supp regions. On theother hand, in the case of sli-RISC, only resected passenger strand canaffect target binding and only can affect the seed region. Since thereporter system used in the experiments in Example 2 herein wassaturated with targets and limited by RNAi triggers and the passengerstrand or the cleaved passenger strand usually gets degraded (Liu et al.2009; Kawamata and Tomari 2010; Ye et al. 2011), the sponge effect fromthe passenger strand will be limited.

An alternative explanation is proposed for the observation shown inExample 2: the difference may result from the participation ofnon-slicing Agos in di-RISCs and the two types of slicing RISCs loadedwith different lengths of guide smRNAs. The tertiary structure of thesefunctional RISCs with different lengths of guide smRNAs may allow themto adapt to different RISC function mechanisms. Although non-slicingAgos can be loaded with pre-miR-451 mimics to form sli-pre-RISCs, onlythe Ago2 loaded form can be further processed to mature sli-RISCs (Duecket al. 2012). Most likely non-slicing Agos loaded sli-smRNAs werereleased and reloaded onto Ago2 for maturation and this may have led tothe previous observation that the silencing action from di-RISC peakedabout 12 hours earlier than that from sli-RISC (Sun et al. 2015). Theresults that sli-siRNAs cannot use the L30 and 3L10 reconstitutedslicing intermediates for function, suggest that the slicing passengerstrand is necessary for activation of sli-RISC and sli-siRNA maturationmay be coupled with its silencing activities; target silencing could beoccurring while the 3′ end is still being trimmed or the trimming is notnecessary (Yoda et al. 2013; Sun et al. 2015). The L23 to L26 forms,which resemble a δ-shaped guide smRNA inside the RISC, the small loopmay be confined inside the niche formed by PAZ, N, and PIWI domains andmaintain RISCs in their slicing-competent conformation (FIGS. 42A, 42B,43). This fits well with the proposed fixed-end working model of RISCs(Jinek and Doudna 2009). Conversely, di-siRNAs can use segmentedpassenger strand and non-slicing Agos for function, indicating that itis not necessary to nick the passenger strand for Ago2-di-RISCsactivation and it is impossible for non-slicing Agos-di-RISCs tocleavage the passenger strand to be activated (Bramsen et al. 2007; Parkand Shin 2015). Instead, it is a two-step process for di-RISCs: duplexsmRNA loading based on the ends thermal dynamic properties and anchoringof the 5′ phosphate group in the MID domain of Agos; guide strandselection which includes duplex wedging by N domain and passenger strandejection (Kawamata and Tomari 2010). Once a mature di-RISC is formed,the seed of the guide strand nucleates its binding to the target, whichalso promotes the 3supp binding to the target and initiates thesilencing function of di-RISCs (Kawamata and Tomari 2010; Park and Shin2015). This activated di-RISC carries a guide RNA that resembles ahorizontal ζ-shaped RNA inside Ago's RNA binding grooves: the 5′ end ofthe strand is anchored to the Mid domain, and the 3′ end of the strandis tethered to the PAZ domain (FIGS. 42A, 42B, and 43). The di-RISCmodel fits well with the proposed two-state RISC working model thatrequires 3supp to bind to both the PAZ and N domains to induce the Ago2conformational change for RISC activation (Jinek and Doudna 2009).

The results provided herein in Example 2 suggest that guide strands fromsli-smRNAs could cause more off-target effects than guide strands fromdi-smRNAs. These results may have revealed a previously unknown pivotalrole in targeting specificity played by Dicer together with non-slicingAgos. This indicates that the Dicer processing step in smRNA biogenesisplays multiple pivotal roles: producing smRNA duplexes, enabling theloading of smRNAs to non-slicing Agos, and enhancing smRNA targetingspecificity by affecting the dynamics of RISC function. Because targetrepression is the dominant gene silencing method adapted in animals, itis conceivable that this kind of natural adaption is driven by selectionpressure of target specificity. It seems that the short length of theseed will broaden the target spectrum at the cost of reduced potency,but this could be overcome by using multiple seed sites to enhanceon-target effects and achieve synergy in both silencing efficacy andspecificity.

The experiments in Example 2 were carried out in a reporter system forhighly complementary targets when targets are saturated and the amountof siRNAs is limited. However, for both research and clinicalapplications, it is usually necessary to use siRNAs at a high dosage toachieve an ideal silencing effect. Therefore, siRNAs are often used atsaturating conditions and the amounts of targets are usually limited bytheir biological expression levels. A carefully designed siRNA shouldavoid targeting highly complementary targets and the number of this kindof target is often very low. It is the seed targeted genes that usuallyexist in hundreds or thousands are really needed to be considered foroff-target effects in RNAi applications (Saxena et al. 2003; Jackson etal. 2006; Grimson et al. 2007). To this end, off-target effects are notavoidable for both sli-smRNAs and di-smRNAs, but the passenger strandactivities from sli-smRNAs are usually reduced by 100 to 1000 fold whencompared to the di-smRNA molecule (Cheloufi et al. 2010; Cifuentes etal. 2010; Yang et al. 2010; Sun et al. 2015), therefore, sli-smRNAs willhave much less off-target effects caused by passenger strand thandi-smRNAs.

Materials and Methods

Cell lines and cell culture. HEK-293 cells were maintained in highglucose (4.5 g/l) DMEM supplemented with 2 mM glutamine, 10% FBS, and 2mM penicillin/streptomycin. Cells were incubated at 37° C., 5% CO2.

Transfection. For reporter assays, RNAi triggers and reporter constructswere co-transfected into cells by using Lipofectamine 2000 (Invitrogen)as previously reported (Sun et al. 2015). For each experiment, at leastthree independent transfections were performed in duplicate in 24-wellplates. Cell were grown to 75 to 85% confluency in 500 μl medium, andwere transfected with luciferase reporter (50 ng), and different amountsof di-siRNA or sli-siRNA (100 ng of stuffer DNA, plus 1 μl of siRNA, and1 μl of Lipofectamine 2000).

Dual-luciferase reporter assays. All reporter assays were performedusing psiCheck 2.0-based, dual-luciferase reporters from Promega thatexpress both firefly luciferase (Fluc) and Renilla luciferase (Rluc).Reporters carried complementary target sequences that were constructedby inserting annealed oligonucleotides into the Xho I/Spe I sites of the3′ UTR of the Rluc gene in psiCheck2.2 vector (Sun et al. 2015). Thesereporters were used to quantify gene silencing. Forty eight hours aftertransfection, cells were lysed with 100 μl passive lysis buffer(Promega) and luciferase levels for 20 μl of lysate were determined(Dual-Luciferase reporter assay kit and GloMax 96 MicroplateLuminometer, Promega). Changes in expression of Rluc (target) werenormalized to Fluc (internal control) and then calculated relative tothe scramble sli-siRNA control. The relative ratios of Rluc/Fluc wereused to measure the efficiency of silencing. Data were averaged fromleast three independent transfections and each transfection had at leasttwo replicates. Error bars indicate the standard deviation.

Oligonucleotides. All oligonucleotides were synthesized by IntegratedDNA Technologies; sequences are listed in the table shown in FIG. 31.

REFERENCES

The references, patents and published patent applications listed below,and all references cited in the specification above are herebyincorporated by reference in their entirety, as if fully set forthherein.

-   1. Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A.,    Weber, K. & Tuschl, T. (2001). Duplexes of 21-nucleotide RNAs    mediate RNA interference in cultured mammalian cells. Nature 411:    494-498.-   2. Doench, J. G., Petersen, C. P. & Sharp, P. A. (2003). siRNAs can    function as miRNAs. Genes Dev 17: 438-442.-   3. Zeng, Y., Yi, R. & Cullen, B. R. (2003). MicroRNAs and small    interfering RNAs can inhibit mRNA expression by similar mechanisms.    Proc Natl Acad Sci USA 100: 9779-9784.-   4. McManus, M. T., Petersen, C. P., Haines, B. B., Chen, J. &    Sharp, P. A. (2002). Gene silencing using micro-RNA designed    hairpins. RNA 8: 842-850.-   5. Brummelkamp, T. R., Bernards, R. & Agami, R. (2002). A system for    stable expression of short interfering RNAs in mammalian cells.    Science 296: 550-553.-   6. Gu, S., Jin, L., Zhang, Y., Huang, Y., Zhang, F.,    Valdmanis, P. N. et al. (2012). The loop position of shRNAs and    pre-miRNAs is critical for the accuracy of dicer processing in vivo.    Cell 151: 900-911.-   7. Herrera-Carrillo, E., Harwig, A., Liu, Y. P. & Berkhout, B.    (2014). Probing the shRNA characteristics that hinder Dicer    recognition and consequently allow Ago-mediated processing and    AgoshRNA activity. RNA.-   8. McIntyre, G. J., Yu, Y. H., Lomas, M. & Fanning, G. C. (2011).    The effects of stem length and core placement on shRNA activity. BMC    Mol Biol 12: 34.-   9. Siolas, D., Lerner, C., Burchard, J., Ge, W., Linsley, P. S.,    Paddison, P. J. et al. (2005). Synthetic shRNAs as potent RNAi    triggers. Nat Biotechnol 23: 227-231.-   10. Ge, Q., lives, H., Dallas, A., Kumar, P., Shorenstein, J.,    Kazakov, S. A. et al. (2010). Minimal-length short hairpin RNAs: the    relationship of structure and RNAi activity. RNA 16: 106-117.-   11. Dallas, A., lives, H., Ge, Q., Kumar, P., Shorenstein, J.,    Kazakov, S. A. et al. (2012). Right- and left-loop short shRNAs have    distinct and unusual mechanisms of gene silencing. Nucleic Acids    Res.-   12. Jackson, A. L., Bartz, S. R., Schelter, J., Kobayashi, S. V.,    Burchard, J., Mao, M. et al. (2003). Expression profiling reveals    off-target gene regulation by RNAi. Nat Biotechnol 21: 635-637.-   13. Jackson, A. L. & Linsley, P. S. (2010). Recognizing and avoiding    siRNA off-target effects for target identification and therapeutic    application. Nat Rev Drug Discov 9: 57-67.-   14. Petri, S. & Meister, G. (2013). siRNA design principles and    off-target effects. Methods Mol Biol 986: 59-71.-   15. Cheloufi, S., Dos Santos, C. O., Chong, M. M. & Hannon, G. J.    (2010). A dicer-independent miRNA biogenesis pathway that requires    Ago catalysis. Nature 465: 584-589.-   16. Cifuentes, D., Xue, H., Taylor, D. W., Patnode, H., Mishima, Y.,    Cheloufi, S. et al. (2010). A novel miRNA processing pathway    independent of Dicer requires Argonaute2 catalytic activity. Science    328: 1694-1698.-   17. Yang, J. S., Maurin, T., Robine, N., Rasmussen, K. D.,    Jeffrey, K. L., Chandwani, R. et al. (2010). Conserved vertebrate    mir-451 provides a platform for Dicer-independent, Ago2-mediated    microRNA biogenesis. Proc Natl Acad Sci USA 107: 15163-15168.-   18. Dueck, A., Ziegler, C., Eichner, A., Berezikov, E. & Meister, G.    (2012). microRNAs associated with the different human Argonaute    proteins. Nucleic Acids Res 40: 9850-9862.-   19. Yang, J. S., Maurin, T. & Lai, E. C. (2012). Functional    parameters of Dicer-independent microRNA biogenesis. RNA 18:    945-957.-   20. Liu, Y. P., Schopman, N. C. & Berkhout, B. (2013).    Dicer-independent processing of short hairpin RNAs. Nucleic Acids    Res 41: 3723-3733.-   21. Ma, H., Zhang, J. & Wu, H. (2014). Designing Ago2-specific    siRNA/shRNA to Avoid Competition with Endogenous miRNAs. Mol Ther    Nucleic Acids 3: e176.-   22. Frank, F., Sonenberg, N. & Nagar, B. (2010). Structural basis    for 5′-nucleotide base-specific recognition of guide RNA by human    AGO2. Nature 465: 818-822.-   23. Elkayam, E., Kuhn, C. D., Tocilj, A., Haase, A. D., Greene, E.    M., Hannon, G. J. et al. (2012). The structure of human argonaute-2    in complex with miR-20a. Cell 150: 100-110.-   24. Sun, G., Wu, X., Wang, J., Li, H., Li, X., Gao, H. et al.    (2011). A bias-reducing strategy in profiling small RNAs using    Solexa. RNA 17: 2256-2262.-   25. Martinez, J., Patkaniowska, A., Urlaub, H., Luhrmann, R. &    Tuschl, T. (2002). Single-stranded antisense siRNAs guide target RNA    cleavage in RNAi. Cell 110: 563-574.-   26. Schwarz, D. S., Hutvagner, G., Du, T., Xu, Z., Aronin, N. &    Zamore, P. D. (2003). Asymmetry in the assembly of the RNAi enzyme    complex. Cell 115: 199-208.-   27. Ma, J. B., Yuan, Y. R., Meister, G., Pei, Y., Tuschl, T. &    Patel, D. J. (2005). Structural basis for 5′-end-specific    recognition of guide RNA by the A. fulgidus Piwi protein. Nature    434: 666-670.-   28. Ramirez, A., Shuman, S. & Schwer, B. (2008). Human RNA 5′-kinase    (hClp1) can function as a tRNA splicing enzyme in vivo. RNA 14:    1737-1745.-   29. Chi, S. W., Hannon, G. J. & Darnell, R. B. (2012). An    alternative mode of microRNA target recognition. Nat Struct Mol Biol    19: 321-327.-   30. Sun, X., Rogoff, H. A. & Li, C. J. (2008). Asymmetric RNA    duplexes mediate RNA interference in mammalian cells. Nat Biotechnol    26: 1379-1382.-   31. Chang, C. I., Yoo, J. W., Hong, S. W., Lee, S. E., Kang, H. S.,    Sun, X. et al. (2009). Asymmetric shorter-duplex siRNA structures    trigger efficient gene silencing with reduced nonspecific effects.    Mol Ther 17: 725-732.-   32. Chu, C. Y. & Rana, T. M. (2008). Potent RNAi by short RNA    triggers. RNA 14: 1714-1719.-   33. Bramsen, J. B., Laursen, M. B., Damgaard, C. K., Lena, S. W.,    Babu, B. R., Wengel, J. et al. (2007). Improved silencing properties    using small internally segmented interfering RNAs. Nucleic Acids Res    35: 5886-5897.-   34. Ge, Q., Dallas, A., lives, H., Shorenstein, J., Behlke, M. A. &    Johnston, B. H. (2010). Effects of chemical modification on the    potency, serum stability, and immunostimulatory properties of short    shRNAs. RNA 16: 118-130.-   35. Grimm, D., Wang, L., Lee, J. S., Schurmann, N., Gu, S.,    Borner, K. et al. (2010). Argonaute proteins are key determinants of    RNAi efficacy, toxicity, and persistence in the adult mouse liver. J    Clin Invest 120: 3106-3119.-   36. Khvorova, A., Reynolds, A. & Jayasena, S. D. (2003). Functional    siRNAs and miRNAs exhibit strand bias. Cell 115: 209-216.-   37. Petri, S., Dueck, A., Lehmann, G., Putz, N., Rudel, S.,    Kremmer, E. et al. (2011). Increased siRNA duplex stability    correlates with reduced off-target and elevated on-target effects.    RNA 17: 737-749.-   38. Neale, B. S., Soifer, H. S., Bowers, C. & Rossi, J. J. (2005).    siRNA target site secondary structure predictions using local stable    substructures. Nucleic Acids Res 33: e30.-   39. Matveeva, O. V., Kang, Y. B., Spiridonov, A. N., Saetrom, P.,    Nemtsov, V. A., Ogurtsov, A. Y. et al. (2010). Optimization of    Duplex Stability and Terminal Asymmetry for shRNA Design. PLoS ONE    5.-   40. Sun, G. & Rossi, J. J. (2009). Problems associated with reporter    assays in RNAi studies. RNA Biol 6: 406-411.-   41. Aagaard, L., Amarzguioui, M., Sun, G., Santos, L. C., Ehsani,    A., Prydz, H. et al. (2007). A facile lentiviral vector system for    expression of doxycycline-inducible shRNAs: knockdown of the    pre-miRNA processing enzyme Drosha. Mol Ther 15: 938-945.-   42. Li, M. J., Bauer, G., Michienzi, A., Yee, J. K., Lee, N. S.,    Kim, J. et al. (2003). Inhibition of HIV-1 infection by lentiviral    vectors expressing Pol III-promoted anti-HIV RNAs. Mol Ther 8:    196-206.-   43. Li, M. & Rossi, J. J. (2008). Lentiviral vector delivery of    siRNA and shRNA encoding genes into cultured and primary    hematopoietic cells. Methods Mol Biol 433: 287-299.-   44. Sun, G., Yan, J., Noltner, K., Feng, J., Li, H., Sarkis, D. A.    et al. (2009). SNPs in human miRNA genes affect biogenesis and    function. RNA 15: 1640-1651.-   45. Zuker, M. (2003). Mfold web server for nucleic acid folding and    hybridization prediction. Nucleic Acids Res 31: 3406-3415.-   46. Hofacker, I. L. (2003). Vienna RNA secondary structure server.    Nucleic Acids Res 31: 3429-3431.-   47. Reuter, J. S. & Mathews, D. H. (2010). RNAstructure: software    for RNA secondary structure prediction and analysis. BMC    Bioinformatics 11: 129.-   48. Waterhouse, A. M., Procter, J. B., Martin, D. M., Clamp, M. &    Barton, G. J. (2009). Jalview Version 2—a multiple sequence    alignment editor and analysis workbench. Bioinformatics 25:    1189-1191.-   49. Parisien, M. & Major, F. (2008). The MC-Fold and MC-Sym pipeline    infers RNA structure from sequence data. Nature 452: 51-55.-   50. Popenda, M., Szachniuk, M., Antczak, M., Purzycka, K. J.,    Lukasiak, P., Bartol, N. et al. (2012). Automated 3D structure    composition for large RNAs. Nucleic Acids Res 40: e112.-   51. Sun, G., Li, H. & Rossi, J. J. (2010). Sequence context outside    the target region influences the effectiveness of miR-223 target    sites in the RhoB 3′UTR. Nucleic Acids Res 38: 239-252.-   52. Brennecke J, Stark A, Russell R B, Cohen S M. 2005. Principles    of microRNA-target recognition. PLoS Biol 3: e85.-   53. Faehnle C R, Elkayam E, Haase A D, Hannon G J,    Joshua-Tor L. 2013. The making of a slicer: activation of human    Argonaute-1. Cell Rep 3: 1901-1909.-   54. Foulkes W D, Priest J R, Duchaine T F. 2014. DICER1: mutations,    microRNAs and mechanisms. Nat Rev Cancer 14: 662-672.-   55. Grimson A, Farh K K, Johnston W K, Garrett-Engele P, Lim L P,    Bartel D P. 2007. MicroRNA targeting specificity in mammals:    determinants beyond seed pairing. Mol Cell 27: 91-105.-   56. Ha M, Kim V N. 2014. Regulation of microRNA biogenesis. Nat Rev    Mol Cell Biol 15: 509-524.-   57. Hauptmann J, Dueck A, Harlander S, Pfaff J, Merkl R,    Meister G. 2013. Turning catalytically inactive human Argonaute    proteins into active slicer enzymes. Nat Struct Mol Biol.-   58. Hauptmann J, Kater L, Loffler P, Merkl R, Meister G. 2014.    Generation of catalytic human Ago4 identifies structural elements    important for RNA cleavage. RNA 20: 1532-1538.-   59. Jackson A L, Burchard J, Schelter J, Chau B N, Cleary M, Lim L,    Linsley P S. 2006. Widespread siRNA “off-target” transcript    silencing mediated by seed region sequence complementarity. RNA 12:    1179-1187.-   60. Jinek M, Doudna J A. 2009. A three-dimensional view of the    molecular machinery of RNA interference. Nature 457: 405-412.-   Kawamata T, Tomari Y. 2010. Making RISC. Trends Biochem Sci 35:    368-376.-   61. Lewis B P, Burge C B, Bartel D P. 2005. Conserved seed pairing,    often flanked by adenosines, indicates that thousands of human genes    are microRNA targets. Cell 120: 15-20.-   62. Lewis B P, Shih I H, Jones-Rhoades M W, Bartel D P, Burge    C B. 2003. Prediction of mammalian microRNA targets. Cell 115:    787-798.-   63. Liu Y, Ye X, Jiang F, Liang C, Chen D, Peng J, Kinch L N,    Grishin N V, Liu Q. 2009. C3PO, an endoribonuclease that promotes    RNAi by facilitating RISC activation. Science 325: 750-753.-   64. Ma H, Zhang J, Wu H. 2014. Designing Ago2-specific siRNA/shRNA    to Avoid Competition with Endogenous miRNAs. Mol Ther Nucleic Acids    3: e176.-   65. Park J H, Shin C. 2015. Slicer-independent mechanism drives    small-RNA strand separation during human RISC assembly. Nucleic    Acids Res.-   66. Saxena S, Jonsson Z O, Dutta A. 2003. Small RNAs with imperfect    match to endogenous mRNA repress translation. Implications for    off-target activity of small inhibitory RNA in mammalian cells. J    Biol Chem 278: 44312-44319.-   67. Schirle N T, Sheu-Gruttadauria J, MacRae I J. 2014. Gene    regulation. Structural basis for microRNA targeting. Science 346:    608-613.-   68. Sun G, Yeh S Y, Yuan C W, Chiu M J, Yung B S, Yen Y. 2015.    Molecular Properties, Functional Mechanisms, and Applications of    Sliced siRNA. Mol Ther Nucleic Acids 4: e221.-   69. Wee L M, Flores-Jasso C F, Salomon W E, Zamore P D. 2012.    Argonaute divides its RNA guide into domains with distinct functions    and RNA-binding properties. Cell 151: 1055-1067.-   70. Ye X, Huang N, Liu Y, Paroo Z, Huerta C, Li P, Chen S, Liu Q,    Zhang H. 2011. Structure of C3PO and mechanism of human RISC    activation. Nat Struct Mol Biol 18: 650-657.-   71. Yoda M, Cifuentes D, Izumi N, Sakaguchi Y, Suzuki T, Giraldez A    J, Tomari Y. 2013. Poly(A)-specific ribonuclease mediates 3′-end    trimming of Argonaute2-cleaved precursor microRNAs. Cell Rep 5:    715-726.

What is claimed is:
 1. A non-naturally occurring short hairpin RNA(shRNA) molecule designed to repress expression of a target gene, thenon-naturally occurring shRNA molecule comprising a nucleotide sequenceselected from the group consisting of SEQ ID NOs 32-40, 42-69, 79-83,88-91, 95, 99, and
 105. 2. The shRNA molecule of claim 1, wherein thetarget gene is ribonucleotide reductase.
 3. The shRNA molecule of claim1, further comprising a phosphate at a 5′ end of the shRNA molecule. 4.The shRNA molecule of claim 1, further comprising a dideoxy C (ddC) at a3′ end of the shRNA molecule.
 5. A vector comprising a nucleotidesequence encoding one or more short hairpin RNA (shRNA) moleculesdesigned to repress expression of a target gene, wherein the nucleotidesequence is selected from the group consisting of SEQ ID NOs 9-10,14-28, 75-77, 85-86, 98, and
 104. 6. The vector of claim 5, wherein thevector comprises nucleotide sequences encoding one, two, three, four,five, six, seven, eight, nine, or ten shRNA molecules.
 7. The vector ofclaim 5, wherein the vector is a lentivirus vector, adenovirus vector,adeno-associated virus, or retroviral vector.
 8. The vector of claim 5,wherein the vector further comprises a nucleotide sequence encoding apromoter.
 9. The vector of claim 8, wherein the promotor is a U6promoter.
 10. The vector of claim 9, wherein the U6 promoter comprisesSEQ ID NO: 143 (U6+MCS) or SEQ ID NO: 144 (U6TO+MCS).
 11. The vector ofclaim 8, wherein the promotor is an inducible promoter, a conditionalpromoter, or a constitutive promoter.
 12. The vector of claim 5, whereinthe target gene is ribonucleotide reductase.
 13. A vector comprising anucleotide sequence expressing one or more short hairpin RNA (shRNA)molecules designed to repress expression of a target gene, wherein theshRNA sequence comprises a nucleotide sequence selected from the groupconsisting of SEQ ID NOs 32-40, 42-69, 79-83, 88-91, 95, 99, and 105.14. The vector of claim 13, wherein the vector comprises nucleotidesequences expressing one, two, three, four, five, six, seven, eight,nine, or ten shRNA molecules.
 15. The vector of claim 13, wherein thevector is a lentivirus vector, adenovirus vector, adeno-associatedvirus, or retroviral vector.
 16. The vector of claim 13, wherein thevector further comprises a nucleotide sequence encoding a promoter. 17.The vector of claim 16, wherein the promotor is a U6 promoter.
 18. Thevector of claim 17, wherein the U6 promoter comprises SEQ ID NO: 143(U6+MCS) or SEQ ID NO: 144 (U6TO+MCS).
 19. The vector of claim 16,wherein the promotor is an inducible promoter, a conditional promoter,or a constitutive promoter.
 20. The vector of claim 13, wherein thetarget gene is ribonucleotide reductase.